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SUMMARY 
Acinetobacter baumannii is a Gram-negative opportunistic pathogen 
causing serious hospital-acquired infections and it has been recently positioned 
as a priority pathogen by the World Health Organization. It has been described 
causing outbreaks worldwide and its antimicrobial resistance has been 
worryingly rising in recent times. A. baumannii usually causes infections such as 
ventilator associated pneumonia, septicaemia, urinary tract infections, wound 
infections or meningitis, especially in compromised patient groups such as 
those admitted to ICU and elderly patients, increasing the mortality rates and 
hospitalization costs. 
Other species belonging to the A. baumannii group are being described 
more often lately as causing infections and sometimes related to antimicrobial 
resistance determinants. 
This work is focused in the study of the A. baumannii isolates recovered 
from clinical samples in the two main hospitals of Cochabamba, Bolivia, 
Hospital Materno-Infantil y Hospital Viedma. 
The present work is divided in four sections. 
Section 1. The epidemiology and antibiotic resistance genes were 
studied in A. baumannii clinical isolates from a Children Hospital. 
Section 2. We studied molecular epidemiology by cgMLST and resistome 
of CRAb isolates from the two main hospitals of the city of Cochabamba. 
Section 3. Study of the mobile genetic elements encoding antibiotic 
resistance genes in A. baumannii isolates belonging to different ICs. 
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Section 4. Identification of Acinetobacter seifertii, an A. baumannii group 
member, isolated from both hospitals in Cochabamba. 
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RESUMEN 
Acinetobacter baumannii es un patógeno oportunista Gram-negativo que 
causa infecciones nosocomiales serias, recientemente ha sido establecido 
como un patógeno prioritario por la Organización Mundial de la Salud. Se ha 
descrito como causante de brotes en todo el mundo y su resistencia a los 
antibióticos ha aumentado preocupantemente en los últimos tiempos. A. 
baumannii normalmente causa infecciones como neumonía, septicemia, 
infecciones del tracto urinario, infecciones de heridas o meningitis; 
especialmente en pacientes comprometidos como los que están en la UCI o los 
ancianos. 
Otras especies pertenecientes al grupo A. baumannii se están 
describiendo como agentes causales de infecciones con más frecuencia 
ultimamente y en algunas ocasiones también están asociadas a determinantes 
de resistencia a antibióticos. 
Este trabajo está enfocado en el estudio de aislamientos de A. 
baumannii de muestras clínicas de los dos hospitales principales de la ciudad 
de Cochambamba, Bolivia. 
Este trabajo está dividido en cuatro secciones. 
Sección 1. El objetivo de este studio fue el análisis y caracterización de 
todos los aislamientos de A. baumannii del Hospital Materno-Infantil de 
Cochabamba entre Abril de 2014 y Mayo de 2015. En un total de 36 
aislamientos, se estudió la presencia de carbapenemasas de tipo D o 
oxacilinasas, blaOXA. (blaOXA-51-like, blaOXA-23-like, blaOXA-58-like, blaOXA-40-like y blaOXA-
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143-like), carbapenemasas tipo B o metalo-β-lactamasas (blaVIM, blaGIM, blaSPM-1, 
blaIMP and blaNDM-1); genes codificantes de enzimas modificadoras de 
aminoglicósidos (ant(2”)-Ia and aac(3)-IIa; aph(3’)-Ia, aac(3)-Ia and aph(3’)-VIa; 
aac(6’)-Ih and aac(6’)-Ib/cr; aac(6’)-IIa) y metilasas (rmtB y rmtC).  
Además, se estudió el perfil de resistencia de los aislamientos a distintos 
antibióticos, se empleó el método de difusión de disco para amikacina, 
ampicilina-sulbactam, cefepime, cefotaxima, ceftazidime, ceftriaxona, 
ciprofloxacino, doxiciclina, gentamicina, imipenem, meropenem, minociclina, 
piperacilina-tazobactam, tetraciclina, tobramicina y trimetoprim-sulfametoxazol; 
se usó E-test para colistina. Se emplearon criterios establecidos para asignar 
los aislamientos a los grupos MDR (multidrug-resistant), XDR (extensively drug-
resistant) o PDR (pandrug-resistant). 
La relación clonal de estos aislamientos se estudió por restricción con la 
enzima ApaI y PFGE; los fragmentos resultants se analizaron con el software 
Fingerprinting II (Bio-Rad) de comparación de perfiles de bandas; el punto de 
corte para asumir relación clonal entre aislamientos se estableció en ≥87%. 
Para estudiar la epidemiología molecular también se empleó el esquema 
Oxford de MLST.  
La localización del gen blaOXA-23-like se analizó mediante restricción con la 
enzima I-Ceu-I, PFGE, Southern blot e hibridación con una sonda marcada con 
digoxigenina. 
También se estudió la producción de biofilm por parte de los 
aislamientos, el ensayo se llevo a cabo en pocillos en los cuales se crecieron 
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los cultivos, posteriormente fueron lavados y teñidos. La formación de Biofilm 
se cuantificó midiendo la cantidad de tinte mediante espectrofotometría. 
Sección 2. Se estudió la epidemiología molecular mediante cgMLST y el 
resistoma de aislamientos CRAb de los dos hospitales principales de 
Cochabamba, Hospital Materno Infantil y Hospital Viedma. En total, 95 
aislamientos se incluyeron en el estudio, que se confirmaron como A. 
baumannii por multiplex PCR del gen gyrB y presencia de blaOXA-51-like. La 
presencia de β-lactamasas de clase D y B se analizó mediante multiplex PCR 
(blaOXA-51-like, blaOXA-23-like, blaOXA-58-like, blaOXA-40-like, blaOXA-143-like y blaOXA-235-like; 
blaVIM, blaKPC, blaNDM y blaOXA-48-like; blaIMI, blaGES, blaGIM, blaIMP e ISAba1- blaOXA-51-
like). Los perfiles de susceptibilidad a antibióticos se testaron mediante dilución 
en agar y microdilución en caldo. Todos los aislamientos resistentes a 
carbapenems, así como cuatro aislamientos sensibles se sometieron a 
secuenciación de genoma completo en la plataforma Illumina MiSeq. Los 
ensamblajes se realizaron con Velvet, Ridom SeqSphere+ v.3.0 y SPAdes 3.9. 
Los ensamblajes se emplearon para obtener el resistoma en ResFinder, los 
STs de los esquemas Oxford y Pasteur y el cgMLST para determiner su 
epidemiología molecular. Se asignaron los aislamientos a los distintos clones 
internacionales (IC) gracias a la variante del gen blaOXA-51-like, el ST del esquema 
Pasteur y el cgMLST. 
Además, también se estudió el contenido plasmídico y la localización de 
los genes de resistencia a antibióticos blaOXA-23 y strA, mediante digestion con 
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la enzima S1 y separación de fragmentos con PFGE, Southern blot e 
hibridación con sondas marcadas con digoxigenina. 
Sección 3. Estudio de elementos genéticos móviles portando genes 
resistencia a antibióticos en aislamientos de A. baumannii pertenecientes a 
diferentes IC. Los datos de la digestion S1-PFGE, Southern blot e hibridaciones 
en conjunto con los  ensamblajes de genoma complete de Velvet, Ridom 
SeqSphere v.3.0, SPAdes y plasmidSPAdes se emplearon para hacer una 
predicción de los ensamblajes de los plásmidos e islas de resistencia 
localizadas en el cromosoma bacteriano, que se confirmaron posteriormente 
mediante PCR. Para confirmar estas estructuras plasmídicas se utilizó la 
técnica de secuenciación MinION de lecturas largas de Oxford Nanopore 
Technologies. Estas lecturas se ensamblaron mediante Canu. Además, las 
lecturas largas de MinION y las cortas, pero más precisas, de MiSeq se usaron 
en un ensamblaje conjunto, hybridSPAdes, en el cual las lecturas largas se 
utilizan como molde para ordenar las cortas de MiSeq.  
Una vez obtenidas las estructuras de los plásmidos y las islas de 
resistencia cromosómicas, se predijeron los marcos de lectura abierta con 
ORFfinder con el fin de conseguir una anotación de los genes presentes. Una 
segunda anotación funcional se consiguió con la herramienta en línea RAST 
(Rapid Annotation Subsystem Technology). Con esta información se diseñaron 
diagramas de los plásmidos y las islas de resistencia con la herramienta 
SnapGene Viewer. 
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Sección 4. Identificación de Acinetobacter seifertii, un miembro del grupo 
A. baumannii, aislado en ambos hospitales de Cochabamba. Tres aislamientos 
identificados como Acinetobacter sp. por los laboratorios de diagnostico de los 
Hospitales Materno Infantil y Viedma, ofrecieron resultados contradictorios en la 
identificación mediante PCR multiplex del gen gyrB, las bandas obtenidas eran 
las específicas de A. baumannii y Acinetobacter pittii. Los equipos 
semiautomatizados VITEK MS y MALDI-TOF MS tampoco fueron capaces de 
ofrecer una identificación clara; el resultado de VITEK MS era A. baumannii 
complex para los tres aislamientos y MALDI-TOF MS daba un perfil mixto de A. 
baumannii y A. pittii.  
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INTRODUCTION 
1. GENUS Acinetobacter 
The genus Acinetobacter belongs to the nonfermenting Gram-negative 
bacilli and it is the second most commonly found genus within this group 
causing bacterial infections. They have been isolated from the environment but 
also from clinical samples and they have became a serious problem in the 
intensive care units worldwide, especially A. baumannii. Acinetobacter is able to 
survive in unfavorable conditions and hospital reservoirs may inlclude 
mattresses, waterbaths and the hands of hospital staff and can cause 
outbreaks (1, 2). Several species within the genus have been reported to carry 
antimicrobial resistance determinants, which can compromise and make difficult 
antibiotic therapy (2–4).  
Clinical Acinetobacter species can be easily grown in solid and liquid 
media at 37°C while the environmental species only grow at lower temperatures 
(20-30°C). All Acinetobacter species are oxidase negative, catalase positive, 
and strictly aerobic (1, 5). 
 
	  
 
 
 
 
 
 
 
Figure 3.	  Acinetobacter baumannii in MacConkey agar. 	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1.1. Historical perspective 
The current designation of the genus as Acinetobacter was first proposed 
by Brisou and Prévot in 1954 based on the  Greek term “akinetos” which means 
non-motile (6), although twiching motility has been described in Acinetobacter 
baumannii (7). In 1968 this classification became widely accepted after the 
study of Baumann et al (8) was published. However, the first isolate of this 
genera was obtained from soil in 1911 and named Micrococcus calcoaceticus 
by Beijerinck (9). 
The genus is still growing and species such as Acinetobacter piscicola 
and Acinetobacter seifertii have been validly named and published. 
 
1.2. Current taxonomy 
Currently, the genus Acinetobacter comprises 58 validly published 
species names, 6 tentative species designation and 9 effectively but not validly 
published species names. 
Table 2. Validly published names, tentative species designation and effectively but not 
validly published species names (http://apps.szu.cz/anemec/Classification.pdf) 
	  
Validly published species name Cultured from 
A. albensis (10) Soil, water 
A. apis (11) Honey bee intestine 
A. baumannii (12) Human, warm-blooded animals 
A. baylyi (13) Activated sludge, soil 
A. beijerinckii (14) Human, animals, soil, water 
A. bereziniae (12, 15) Human 
A. bohemicus (16) Soil, water 
A. boissieri (17) Floral nectar 
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Table 1. Continued. 
A. bouvetii (13) Activated sludge 
A. brisouii (18) Peat 
A. calcoaceticus (12) Soil, water, human 
A. celticus (19) Soil, water 
A. colistiniresistens (20, 21) Human 
A. courvalinii (21, 22) Human, animals 
A. defluvii (23) Hospital sewage 
A. dijkshoorniae (=A. lactucae) (24, 25) Human, water 
A. dispersus (21, 22) Soil, water, human 
A. equi (26) Horse 
A. gandensis (27) Horse, cattle, water 
A. gerneri (13) Activated sludge 
A. grimontii (=A. junii) (13, 28) Activated sludge 
A. guangdongensis (=A. indicus) (29, 30) Lead-zinc ore 
A. guillouiae (12, 15) Soil, water, human 
A. gyllenbergii (14) Human 
A. haemolyticus (12) Human 
A. halotolerans (31) Soil 
A. harbinensis (32) River water 
A. indicus (33) Soil 
A. johnsonii (12) Soil, water, human, animals 
A. junii (12) Human, animals, water, soil 
A. kookii (34) Soil, water 
A. lactucae (25) Lettuce 
A. larvae (35) Moth larval gut 
A. lwoffii (12, 36) Human, animals, soil, water 
A. modestus (22, 37) Human, water 
A. nectaris (17) Floral nectar 
A. nosocomialis Human 
A. pakistanensis (=A. bohemicus) (38, 39) Wastewater 
A. parvus (40) Human, animals 
A. pittii (12, 41) Human, soil, water 
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Table 1. Continued.	  
 
 
A. piscicola (42) Fish  
A. populi (43) Populus bark 
A. pragensis (44) Soil, water 
A. proteolyticus (22, 37) Human 
A. puyangensis (45) Populus bark 
A. qingfengensis (46) Populus bark 
A. radioresistens (12, 47) Human, soil, cotton 
A. rudis (48) Raw milk, wastewater 
A. schindleri (49) Human, animals 
A. seifertii (50, 51) Human 
A. soli (52) Human, soil 
A. tandoii (13) Activated sludge, water, soil 
A. tjembergiae (13) Activated sludge 
A. towneri (13) Activated sludge, water, soil 
A. ursingii (49) Human 
A. variabilis (53) Human, animals, soil 
A. venetianus (54, 55) Salt water 
A. vivianii (22, 37) Human, soil, water 
Tentative species designation Cultured from 
Genomic sp. 6 (12) Human 
Genomic sp. 15BJ (21) Human 
Genomic species 16 (21) Human 
Taxon 21 (37) Human 
Taxon 22 (37) Human 
Taxon 23 || (12, 37) Soil, water, animals,human 
Effectively but not validly published 
species name 
Cultured from 
A. antiviralis (56) Tobacco plant roots 
A. kyonggiensis (57) Sewage treatment plant 
A. marinus (58) Sea water 
A. oleivorans (59) Soil 
A. oryzae (= A. johnsonii) (60) Rice 
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It is important to highlight that A. baumannii together with A. 
calcoaceticus, A. nosocomialis, A. pitti, A. seifertii and A. dijkshoorniae (=A. 
lactucae) form the so called Acinetobacter calcoaceticus- Acinetobacter 
baumannii complex (ACB) (24, 50, 65). These ACB species are clinically 
relevant as are often isolated from clinical sample and are difficult to distiguish 
phenotypically. . 
 
1.3. Habitat 
Acinetobacter spp. can be isolated from a wide range of sources. 
Different species have been recovered from environmental samples such as 
soil or water (10, 12, 14–16, 19, 22, 32, 33), companion animals or cattle (12, 
14, 22, 26, 27, 53), plants such as lettuce or cotton (12, 25, 47) and even from 
the digestive tract of insects (11, 35). The presence of these organisms in such 
different habitats led to the consideration that some of them could be ubiquitous 
in nature.  
Some Acinetobacter species are known to be part of the normal 
microbiota in humans (5, 66) while the habitat of A. baumannii, the most 
relevant clinical species, remains unknown. It has been rarely found as a 
Table 1. Continued.  
A. plantarum (= A. junii) (61) Wheat 
A. refrigeratoris (= A. variabilis) (62) Refrigerator 
A. seohaensis (= A. towneri) (58) Sea water 
A. septicus (= A. ursingii) (63, 64) Human 
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colonizer among healthy individuals. However, A. baumannii has been isolated 
from several sources, human lice, vegetables and from hospital equipment such 
as mattresses, ventilator tubing or respirometers, and taken together with the 
high survival rates of Acinetobacter baumannii, creates a perfect source of 
infection that can cause outbreaks (67). 
 
1.4. Species identification 
Species identification within the genus Acinetobacter is difficult due to the 
similarities among them. Different methods have been described and used 
along the years, while the phenotypic methods are not easy to perform and 
unsuited for diagnostic purposes, while molecular techniques show a better 
species identification (68). 
The gold-standard method for species delineation (within the 
Acinetobacter genus) is DNA-DNA hybridization, DDH, (12) while it can be used 
for species identification, it is very laborious and can not be used in the 
diagnostics’ laboratories routine.  
There are other techniques based on DNA fingerprinting, such as 
Amplified Ribosomal DNA Restriction Analysis (ARDRA), Amplified Fragment 
Length Polymorphism (AFLP), and ribotyping. ARDRA is based on the 
amplification and digestion with restriction enzymes (AluI, CfoI, MboI, RsaI and 
MSpI) of a 16S rDNA PCR amplicon. The resultant pattern can be then 
compared with known ones (69); in AFLP the complete bacterial genome is 
digested with HindIII and TaqI, then a selective PCR-amplification using 
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adapters is made to obtain the DNA fingerprints and compare them (70).  
With ribotyping, the complete bacterial DNA is digested, separated by 
electrophoresis, transferred to a membrane by Southern blot and then 
hybridized with a labeled probe for rDNA, the resulting profile is species specific 
(71). 
In order to avoid time-consuming laborious techniques, more specific 
procedures based on sequencing have been developed. These methods rely on 
the amplification and sequencing of different genes and the comparison of the 
sequence to type strains. Different genes are used: 16S-23S rRNA spacer 
region (72), 16S rRNA (73), recA (74) and partial rpoB (68). 
A gyrB multiplex PCR has been also designed to differentiate between 
species within the ACB complex (A. baumannii, A. nosocomialis, A. 
calcoaceticus and A. pittii); it is based on the interspecies heterogenicity and 
specific primers for each species are used (75, 76). 
Figure 4. gyrB multiplex PCR, primers and PCR products (76). 
Another method that has been described for the identification of A. 
baumannii isolates is the detection of the intrinsic blaOXA-51-like carbapenemase 
encoding gene (77), even though further studies revealed that the detection of 
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blaOXA-51-like on its own might lead in some cases to erroneous results (78) and 
other species than A. baumannii such as A. nosocomialis and A. seifertii have 
been found to carry blaOXA-51-like on plasmids (79). 
The most commonly used identification methods in diagnostic 
laboratories are semi-automated systems such as VITEK 2 (80) and MALDI-
TOF MS (Matrix Assisted Laser Desorption-Ionization Time of Flight Mass 
Spectrometry) (81). When using MALDI-TOF MS, bacterial isolates are mixed 
with an organic matrix suitable for the equipment that crystalizes both matrix 
and sample, then the laser in a process called soft-ionization is able to separate 
the sample that will be analyzed and detected acording to its mass and time of 
flight of the different molecules, giving a spectral pattern. Every species has its 
own mass spectrum, which can be compared to a database to obtain the 
species of the unknown bacteria. As with all methods relying on databases, it is 
very useful for identifying already known ones, but will result in misidentification 
of the species that are not included in the database (81, 82). The VITEK 2 
system identifies the pathogens by detecting metabolic activities such as 
acidification, alkalinisation, enzyme hydrolysis and growth in the presence of 
inhibitory substances using a fluorescence-based method, but again this system 
faces the same problems as MALDI-TOF MS, relying on databases of already 
known organisms, and in addition, both of them rely on phenotypic 
characteristics for the identification (80, 83). 
Nowadays, with the use of next generation sequencing and the 
availability of a great number of complete genomes, new methods have arisen 
with the purpose to make identification more accurate (84, 85). As the gold 
	   INTRODUCTION 	  
	   	   	  26	  
standard for species identification is still DDH, a new approach to this technique 
has been developed using whole genome sequencing (WGS) data and an in 
silico method, the digital DNA-DNA hybridization (dDDH) with a threshold >70% 
to identify the same species (86) (http://ggdc.dsmz.de). Another reliable 
technique using WGS data is the calculation of the average nucleotide identity 
(ANI) based on BLAST+ using the online tool JSpecies WS 
(http://jspecies.ribohost.com/jspeciesws/) (87), the identity has to be higher than 
95% to be identified as the same species. In these two identification methods it 
is important to use type strains for comparison, as this is the official reference to 
which all others should be compared. 
 
1.5. Molecular typing 
After identification, typing is used in order to know the relationship among 
the isolates, species population. This can be achieved by different methods that 
are able to discriminate one strain from another, but it should be noted that 
these methods have different discriminatory power. The analysis of isolates’ 
clonality within a group is important to know if the cases are unrelated or if there 
is an outbreak i.e. transmission of a strain, because it will allow having a deeper 
knowledge of the strains circulating, identifying the most virulent clones, and 
establishing what infection control procedures are needed, i.e. patients 
quarantine, identification of the source and decontamination of equipment. 
Since A. baumannii is an opportunistic pathogen, it is important to study 
its epidemiology in order to prevent its spread, and establish infection control 
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plans as well as analyze the outbreak. Almost all the typing methods are 
focused in A. baumannii as it is the most relevant clinical species of the genus. 
Different methods are available for this purpose. Pulsed Field Gel 
Electrophoresis (PFGE) is the Gold Standard for outbreak analysis (88). It 
consists of digesting the whole bacterial genome with an enzyme (ApaI) and 
then separating the resulting fragments in an agarose gel by electrophoresis 
switching the angle of the electric current. By this method high molecular weight 
DNA bands can be separated. The band pattern shows the relation among the 
isolates and it can be analysed by bioinformatics tools or following the Tenover 
criteria that classifies the isolates in four groups (indistinguishable, closely 
related, possibly related, and different) according to the differences among the 
band patterns (0, 2-3, 4-6, and ≥7, respectively (89).  
Another method that has been used in the past two decades to study the 
clonal relatedness of the isolates have been described with two different 
schemes, it is called multi locus sequence typing (MLST) (90, 91). Both 
methods rely on the analysis of the sequences of seven housekeeping genes, 
each different allele for the gene has a different number and the combination of 
the seven numbers creates a profile for the isolate, called sequence type (ST), 
that can be easily compared in the online database to other STs 
(https://pubmlst.org/abaumannii/). The first scheme is called Oxford (90) and it 
uses the partial sequences of gltA (citrate synthase), gyrB (DNA gyrase subunit 
B), gdhB (glucose dehydrogenase B), recA (homologous recombination factor), 
cpn60 (60-kDa chaperonin), gpi (glucose-6-phosphate isomerase) and rpoD 
(RNA polymerase sigma factor); the second scheme is Pasteur (91) and 
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analyses partial sequences of the following genes cpn60 (60-kDa chaperonin), 
fusA (elongation factor EF-G), gltA (citrate synthase), pyrG (CTP synthase), 
recA (homologous recombination factor), rplB (50S ribosomal protein L2) and 
rpoB (RNA polymerase subunit B). Different STs that share at least 5 (double 
locus variant, DLV) or 6 (single locus variant, SLV) of the seven alleles, form 
clonal complexes (CCs). This method has a good performance for 
epidemiological studies but it lacks the capacity to perform a fine typing, 
especially the Pasteur scheme which has been already reported to have a lower 
discrimination capacity that the Oxford scheme (92). Another strength of this 
method is that can be applied to other especies within the genus. 
The newest developed technology in order to deeply analyse the 
molecular epidemiology of A. baumannii is based in whole genome sequencing 
(93) and the comparison of a core genome, cgMLST. It is similar to MLST but 
the comparison is made among many more genes. The genome of A. 
baumannii ACICU strain was used as the reference genome to define the core 
genome, which was defined up to 2390 genes. Since this method compares 
over 50% of the genome, it supposes high resolution and discrimination among 
isolates (94). 
 
1.6. Clinical relevant species 
Not all the Acinetobacter species are clinically relevant, some of them 
have been reported to cause serious infections. The most important pathogen in 
the genus is A. baumannii, which has been isolated worldwide, causing severe 
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and prolonged outbreaks in hospitals, and it is often related to antimicrobial 
resistance (5, 95). Other species of the genus such as A. nosocomialis and A. 
pitti have been also described as important pathogens and they are difficult to 
distinguish, therefore these three species constitute the A. baumannii group (Ab 
group) (5, 96). There are two recently additions to this group, A. seifertii and A. 
dijkshoorniae. Both of these species have been isolated from clinical samples 
and can carry antimicrobial resistance genes (4, 97). 
 
 Acinetobacter baumannii 1.6.1.
Infections caused by Acinetobacter, presumably A. baumannii, have 
been reported since the 1960s, in reports from Europe and North America. Most 
of the isolates in that time were susceptible to treatments with β-lactams or 
sulphonamides, in contrast to A. baumannii infections nowadays. By the end of 
1970s, this organism was already resistant to aminoglycosides, β-lactams and 
sulphonamides (95). 
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Figure 3. Top diagram shows dates of introduction of antimicrobials. The graph shows 
the date of introduction of antimicrobials, date of first reports of antimicrobial resistance 
in A. baumannii and the emergence of multidrug-resistant (MDR), extensively drug-
resistant (XDR) and pandrug-resistant (PDR) (95). 
 
Thanks to the species description in 1986 by Bouvet & Grimont (12) it 
was possible to more accurately identify to the species level the agent 
responsible for the infection, and not surprinsingly, most of the infections that 
were caused by Acinetobacter sp. were in fact caused by Acinetobacter 
baumannii.  
By the end of the 1990s, multidrug-resistant A. baumannii causing 
nosocomial infections had been reported worldwide. 
The most common clinical manifestations of Acinetobacter baumannii 
infections are as follows (5): 
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• Hospital acquired pneumonia: in almost all the studies the majority of the A. 
baumannii isolates are from the respiratory tract of the patients. It is known 
that the use of mechanical ventilators increase the risk of developing a 
ventilator-associated pneumonia caused by A. baumannii (5). This kind of 
infections are normally related to debilitated patients in ICUs (98). 
• Community-acquired pneumonia: this has been described to happen in 
tropical areas, mostly in patients with a history of alcohol abuse. It has a 
mortality rate between 40-60% (5). In northern Australia, 10% of severe 
community-acquired pneumonia are caused by A. baumannii (98). 
• Bloodstream infection: in a study carried between 1995 and 2002 in the 
USA, A. baumannii was responsible for 1.3% of monomicrobial bloodstream 
infections and the rate was higher among the ICU-acquired bloodstream 
infections (1.6%). The mortality was 34% to 46% in the ICU, the third 
highest mortality rate (5). Another study carried out in Korea analysed 180 
Acinetobacter spp. isolated from bacteremia patients between 2003 and 
2010, and A. baumannii comprised the 50% of the isolates, with a mortality 
more than double in the patients with A. baumannii bloodstream infection 
(96). The most common sources of A. baumannii bloodstream infections 
were vascular catheters and the respiratory tract; less common sources 
were the urinary tract and wounds (98). Some associated risk factors were 
mechanical ventilation, prior surgery, ICUs, prior treatment with broad-
spectrum antibiotics, immunosuppression, burns, wounds, catheters and 
prolonged hospital stays (98). 
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• Skin, soft tissue and bone infection: A. baumannii can infect surgical or 
traumatic wounds, which can lead to osteomyelitis or severe tissue infection 
(98). These infections are normally related to prosthetic material and there 
has been an increase in reports of Acinetobacter spp. causing infections 
after war injuries or natural disasters such as earthquakes; Acinetobacter 
spp. were the most frequently isolated pathogens in wound infections and 
bloodstream infections in patients of the Vietnam war. In addition, an 
increase from 4% to 55% in the infections (respiratory tract, wound 
infections, bloodstream infections) caused by MDR A. baumanii in US 
military casualties injured in Iraq and Afghanistan was reported in a 
retrospective study (99). 
• Urinary Tract Infection: different studies reported the presence of A. 
baumannii as the causative agent of urinary tract infection, but it is normally 
related to catheter-associated patients and its prevalence is always below 
5% (100, 101). 
• Meningitis: nosocomial meningitis caused by A. baumannii is related to prior 
neurosurgical procedures, and the mortality rate associated to this episode 
is 40% (91, 102). 
 
 Acinetobacter seifertii 1.6.2.
Acinetobacter seifertii is a relatively new species within the genus 
Acinetobacter, named in 2015 by Nemec et al (50). The first two strains of this 
species were isolated in 1990-1991 from human clinical samples (ulcer and 
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blood) in Denmark (51). Since then, A. seifertii has been isolated from diverse 
clinical samples such as blood cultures or respiratory tract samples (4, 50, 103), 
and in some cases it carried antimicrobial encoding genes. It has also been 
isolated from the environment, inside (50) and outside the hospital (104). 
• Bloodstream infection: in the majority of the reports A. seifertii causes 
bloodstream infections in Denmark, Japan, the United States of America 
and Norway (50, 51, 103). 
• Ulcer: an ulcer was one of the first sources from which A. seifertii was 
recovered in Denmark (51).  
• Respiratory tract infection: isolates of A. seifertii causing respiratory tract 
infections have been reported in Spain, the Czech Republic, China and 
Brazil (4, 50, 105, 106). The isolates found in Spain and Brazil carried the 
blaOXA-58 carbapenemase encoding gene. 
 
2. VIRULENCE OF Acinetobacter baumannii 
A. baumannii is an important nosocomial pathogen and this is, in part, 
due to its capacity to persist in the hospital environment, and the plasticity of its 
genome to acquire antimicrobial resistance determinants. Although its 
pathogenicity is not completely known, diverse virulence factors have been 
described.  
2.1. Biofilm formation 
A. baumannii is capable of forming biofilms, which are extracellular 
matrices that encase the bacteria within, and constitute a protection against 
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different hazards such as antimicrobials, macrophage attacks, desiccation, and 
disinfectants. Moreover, biofilms are often polymicrobial, creating the perfect 
environment for horizontal gene transfer, contributing to the spread of 
antimicrobial resistance determinants (107). It is known that biofilms are related 
to medical-device associated infections as biofilms are formed both in abiotic 
and biotic surfaces. For example, robust A. baumannii biofilms were found in 
skin and soft tissue infections as well as in health-care associated equipment 
such as catheter or endotracheal tubes.  Factors related to biofilm formation can 
include: quorum sensing which is the capacity of the bacteria to secrete 
chemical signals in order to communicate to the others and measure cell 
density; the csuE gene encodes for the formation and assembly of pili, which 
are needed for adhesion to surfaces; the bap gene encoding for biofilm-
associated proteins that have a role in cell-cell adhesion and maturation of the 
biofilm; RTX-like domain-containing protein that mediates biofilm production; 
PNAG (poly-β-1,6-N-acetylglucosamine), this extracellular polysaccharide has a 
role in surface and cell-to-cell adherence and it also protects bacteria against 
host defenses; OmpA, this outer membrane protein is involved in the bacterial 
attatchment to biotic surfaces; Ata, Acinetobacter trimeric autotransporter, 
contribute to adherence to extracellular matrix components (108–111). 
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Figure 4. Scanning electron microscopy (SEM) of a biofilm-forming A. baumannii strain 
in liquid medium (108). 	  
2.2. Surface polysaccharides 
The capsule in A. baumannii is considered to have an important role in 
virulence. The genes ptk (putative protein tyrosine kinase) and epsA 
(polysaccharide export outer membrane protein) are important for capsule 
polymerization and assembly, which is important for survival in human serum. 
PNAG, which was already described as an important component of the biofilm, 
also protects the bacteria against innate defenses (108). 
 
2.3. Outer membrane proteins (OMPs) 
OmpA protein from A. baumannii is involved in adhesion and invasion of 
epithelial cells and induces their apoptosis, which disrupts the mucus and helps 
bacteria to be internalised through the damaged epithelium. It is also related to 
complement resistance, increasing the capacity to cause bacteremia (108). 
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2.4. Outer membrane vesicles (OMVs) 
OMVs have a very diverse composition (lipopolysaccharides, lipids, 
OMPs and DNA or RNA). Substances related to quorum sensing, transport of 
virulence factors or gene transfer are some of the roles OMVs play in A. 
baumannii virulence (108). 
 
2.5. Proteolytic activity  
Phospolipase C and D are important for human serum resistance, 
epithelial cell invasion, dissemination of bacteria, and have an important role in 
cytotoxicity (108). 
 
2.6. Production of siderophores 
Siderophores are structures related to iron uptake, this mechanism 
constitutes a virulence factor because it allows the bacteria to grow under iron-
limited conditions by acquiring iron from the host, the most important 
siderophore in A. baumannii is acinetobactin (108).   
 
2.7. Penicillin-binding proteins (PBPs) 
These proteins catalyse the synthesis of peptidoglycan, the main 
component of the cell wall; they are also associated with cell division. The PPB-
7/8 is related to cell morphology, growth and survival of A. baumannii, and 
serum resistance (108). 
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3. ANTIMICROBIALS FOR THE TREATMENT OF A. baumannii INFECTION 
An antimicrobial is an agent that works be either killing the 
microorganisms or inhibiting their growth. An antimicrobial that can kill bacteria 
are called bactericidal, while those that stop their growth are called 
bacteriostatic. They can also be grouped according to the use they are given; 
disinfectants are antimicrobials that are used in abiotic surfaces such as the 
floor or clothes; antiseptics are used in biotic surfaces such as the skin prior to 
surgery, and antibiotics are used to treat patients with an infection. 
There are several antimicrobial classes with different targets and sites of 
action, specific agents for the treatment of A. baumannii will be explained below 
in detail and a resume is shown in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanisms of action of different antimicrobials in Gram-negative 
bacteria. 	  
	   INTRODUCTION 	  
	   	   	  38	  
3.1. Aminoglycosides 
Aminoglycosided are a dose-dependent class of antibiotic that inhibits 
protein synthesis. They are produced by Streptomyces spp. and 
Microsmonospora spp. Aminoglycosides bind to the 30s ribosomal subunit, 
leading to the genetic code being misread, and causing an abnormal translation 
generating non-functional proteins. Examples of aminoglycosides that can be 
used to treat A. baumannii infections are amikacin, gentamicin, netilmicin and 
tobramycin. Due to their nephrotoxicity and ototoxicity, their use is restricted to 
severe infections such as extreme cases of sepsis (112).  
 
3.2. β-lactams  
This class of antibiotics kill bacteria by inhibiting the wall synthesis. All of 
them have a β-lactam ring and it targets the penicillin-binding proteins (PBPs) in 
the periplasm, which are involved in the wall synthesis. Penicillins (e.g. 
ampicillin, amoxicillin, piperacillin, ticarcillin, oxacillin), cephalosporins (e.g. 
cefotaxime, ceftazidime, ceftriaxone), carbapenems (e.g. imipenem and 
meropenem) and monobactams (e.g. aztreonam) are the four groups of 
antibiotics that constitute the class β-lactams. Within the group of the β-lactams, 
carbapenems exhibit the broadest spectrum and they, especially imipenem and 
meropenem, are normally used as the last resort treatment in critical patients 
(112, 113). 
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3.3. Fluoroquinolones 
Fluoroquinolones are derived from quinolones, both of which are semi-
synthetic compounds. Upon entering the bacterial cell, they bind to the DNA 
gyrase (topoisomerase II) and topoisomerase IV, which interrupts or blocks 
DNA replication, transcription and cell division. Some fluoroquinolones used for 
the treatment of A. baumannii infections are ciprofloxacin, levofloxacin, 
moxifloxacin or norfloxacin. (112). 
 
3.4. Polymyxins 
The polymyxins act upon the cell membrane, disrupting the phospholipid 
bilayer by a detergent-like action; this increases cell permeability and destroys 
the ability to act as an osmotic barrier, which leads to bacterial death. 
Polymixins can also affect eukaryotic cells’ membranes; which is why they are 
nephrotoxic. Polymixin B and colistin (polymixin E) form the group and are used 
in infections caused by gram negatives resistant to penicillins or other broad-
spectrum antibiotics (112). 
 
3.5. Diaminopyrimidines-Sulfonamides 
Trimethoprim-sulfamethoxazole (co-trimoxazole) interferes with the folic 
acid pathway. Sulfamethoxazole, (a sulfonamide), works at the beginning of the 
pathway, inhibiting the de novo synthesis of dihydropteroic acid; while 
trimethoprim works at the end of the pathway, working as a competitor of 
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dihydrofolate reductase, inhibiting the synthesis of tetrahydrofolic acid in the 
bacteria. The effect of these combination is the blocking of the production of 
folic acid by the bacteria that is needed for the biosynthesis of many cellular 
components. 
 
3.6. Tetracyclines 
Tetracyclines bind to the 30s ribosomal subunit preventing the 
attatchment of the tRNA. Thus the addition of amino acids to the peptide chain 
is stopped, preventing protein synthesis. Examples of tetracyclines are 
doxycycline, minocycline, tetracycline and tigecycline (112). 
 
3.7. First line agents and alternative agents for resistant organisms 
Antibiotic-susceptible A. baumannii infections have a broad range of 
therapeutic options such as broad-spectrum cephalosporin (ceftazidime or 
cefepime), β-lactam combined with a β-lactamase inhibitor (ampicillin-
sulbactam) or a carbapenem (imipenem, meropenem or doripenem). 
Sometimes these agents are used in combination with antipseudomonal 
fluoroquinolones (e.g. imipenem + ciprofloxacin) or aminoglycosides (e.g. 
imipenem + amikacin) (114). 
When A. baumannii isolates are resistant to already mentioned 
antimicrobials, the options for treatment are limited. Polymixins are the first 
choice when treating carbapenem-resistant A. baumannii, but these agents are 
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nephrotoxic and neurotoxic. Minocycline is another agent of use but few data 
about its outcome is available. Combination therapy is also used to treat difficult 
infections but there is not enough data to support or reject this approach, i.e. a 
polymixin plus a carbapenem (114). 
 
4. ANTIMICROBIAL SUSCEPTIBILITY TESTING 
There are different methods to test the antimicrobial susceptibility of 
clinical isolates. 
 
4.1. Disk diffusion method 
The oldest and most widely used is the Kirby-Bauer disk diffusion 
method. The EUCAST (European Committee on Antimicrobial Susceptibility 
Testing) disk diffusion is a standarized method based on studies and 
experience of some expert groups (115). Discs containing known 
concentrations of antibiotics are placed on Mueller-Hinton plates inoculated with 
a swab with a 0.5 McFarland (1-1.5·108 CFU/mL) of the organism in saline 
solution. The antibiotic diffuses through the medium and inhibits bacterial 
growth, this inhibition can be measured and establish whether the isolate is 
susceptible or resistant to the tested antimicrobial. The procedure as well as the 
breakpoints are available for interpretation (115, 116).  
This method is useful to know if the isolate is susceptible or resistant to 
certain antimicrobial but it is not able to get the minimal inhibitory concentration 
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of the antimicrobials, which is the lowest concentration that is able to inhibit 
bacterial growth. 
 
 
4.2. Agar dilution method 
This method is used in order to determine the minimum inhibitory 
concentration (MIC) of an antimicrobial agent against the bacterium, the results 
obtained by this technique are more accurate than those obtained by disk 
diffusion. Plates of Mueller-Hinton agar with increasing concentration of 
antibiotic are prepared and several isolates are inoculated on the same plate. 
The MIC is the lowest concentration of the antibiotic that inhibits the growth of 
the bacteria. 
La parte de imagen con el identificador de relación rId33 no se encontró en el archivo.
Figure 6. Disk diffusion method with inhibition areas (197).  
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The breakpoints for the controls as well as the isolates can be checked in 
the EUCAST breakpoints table (116).  
 
 
4.3. Broth microdilution method 
This method has been set as the only valid one in order to test MICs of 
antimicrobials such as colistin (polymyxin E), because colistin molecule is large 
and it is no able to diffuse in the agar plates. The principle of the technique is 
the same as in agar dilution, but using Mueller-Hinton broth instead of agar. 
Quality control has to be performed with E. coli ATCC 25922 or P. aeruginosa 
ATCC 27853 and with the colistin resistant E. coli NCTC 13846 (116, 117). 
 
 
Figure 7. Agar dilution method testing 18 isolates 
and three controls. 
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4.4. Multidrug-resistant, Extensively drug-resistant and Pandrug-resistant 
In the last years, antimicrobial resistance rates have risen among the 
most common nosocomial pathogens. Because different terminology was being 
used to define the antimicrobial resistance patterns among the isolates, the 
European Centre for Disease Prevention and Control (ECDC) and the Centers 
for Disease Control and Prevention (CDC) gathered an expert committee to 
create a standardized international definition. This criterion was based on the 
Clinical Laboratory Standards Institute (CLSI), the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) and the United States Food and 
Drug Administration (FDA). The antimicrobial categories, agents and criteria 
used to define MDR, XDR and PDR Acinetobacter spp. can be seen in Table 2. 
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Table	  2.	  Antimicrobial categories and antimicrobial agents used to define MDR, XDR and 
PDR in Acinetobacter spp.	  
Antimicrobial category Antimicrobial agent 
Aminoglycoside 
Gentamicin 
Tobramycin 
Amikacin 
Netilmicin 
Antipseudomonal carbapenems 
Imipenem 
Meropenem 
Doripenem 
Antipseudomonal fluoroquinolones Ciprofloxacin Levofloxacin 
Antipseudomonal penicillins 
+ β-lactamase inhibitors 
Piperacillin-tazobactam 
Ticarcillin-clavulanic acid 
Extended-spectrum cephalosporins 
Cefotaxime 
Ceftriaxone 
Ceftazidime 
Cefepime 
Folate pathway inhibitors Trimethoprim-sulphamethoxazole 
Penicillins + β-lactamase inhibitors Ampicillin-sulbactam 
Polymyxins Colistin Polymyxin B 
Tetracyclines 
Tetracycline 
Doxycicline 
Minocycline 
Criteria for defining MDR, XDR and PDR in Acinetobacter spp. 
MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories 
XDR: non-suscpetible to ≥1 agent in all but ≤2 categories 
PDR: non-susceptible to all antimicrobial listed 
 	   
5. MECHANISMS OF ANTIMICROBIAL RESISTANCE 
Resistance to antimicrobials can be innate (intrinsic to a species), or 
acquired. For example, A. baumannii can carry genes conferring resistance to 
antimicrobials in both the chromosome and plasmids and this is in part due to 
its ability to acquire antimicrobial resistance determinants (118). For example 
oxacillinases, blaOXA-23-like, blaOXA-40-like, blaOXA-143-like or blaOXA-235-like, have been 
reported worldwide. Some point mutations have been also described to be 
involved in increased antimicrobial resistance (5). Another mechanism of 
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resistance is the modification of the target site, which impairs its binding and 
activity (5). 
5.1. β-lactamases 
Inactivation of β-lactams is mainly produced by β-lactamase enzymes 
(bla). According to sequence homology, β-lactamases are grouped into four 
classes, A, B, C and D. Class A, C and D have serine at the active site while 
class B have zinc. 
Class A β-lactamases hydrolyze penicillins and cephalosporins and are 
inhibited by clavulanate. Some of them are narrow-spectrum while others are 
extended-spectrum β-lactamases (ESBLs). ESBLs are enzymes that confer 
resistance to β-lactam antibiotics such as penicillins and cephalosporins. 
Diverse class A β-lactamases have been described in A. baumannii isolates: 
TEM-1, TEM-92, GES-1, PER-1, PER-2, CTX-M-2, SCO-1, VEB-1 (118). The 
blaVEB-1 has been described to be associated with an upstream IS (IS26) that 
could be responsible for its spread (5). 
Class B β-lactamases are also called metallo-β-lactamases (MBLs) and 
their activity is dependant on metals such as zinc. As their substrate spectrum is 
broad, they can hydrolyze almost all β-lactams. MBLs described in A. 
baumannii blaIMP-like, blaVIM-like, blaNDM-1, blaSIM-1, blaSPM-1 and blaGIM-1 (118). 
A. baumannii carries an intrinsic chromosomally encoded class C β-
lactamase, AmpC cephalosporinase (ADC, Acinetobacter derived 
cephalosporinase), which is sometimes found with an upstream IS (ISAba1) 
which provides a strong promoter and leads to its overexpression (5). These β-
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lactamases complicate the therapeutic treatment as they confer resistance to 
cephamycins, penicillins and cephalosporins, in addition they are not inhibited 
by β-lactamase inhibitors (118). 
Class D β-lactamases are the most frequently detected carbapenem-
hydrolyzing enzymes within A. baumannii isolates. They are called OXAs 
(oxacillinases) and there are six major subgroups associated with A. baumannii; 
the intrinsic blaOXA-51-like, and the acquired blaOXA-23-like, blaOXA-40-like, blaOXA-58-like, 
blaOXA-143-like and blaOXA-235-like. Most of these enzymes have been, since they 
were first detected, reported worldwide i.e. blaOXA-23-like, blaOXA-40-like and blaOXA-
58-like. Some of these enzymes are associated with upstream insertion elements 
such as ISAba1, ISAba2, ISAba3, leading to their overexpression (5, 118). 
 
5.2. Genome plasticity 
A. baumannii has been shown to have a great genome plasticity, which is 
the capacity to acquire and disseminate genes, especially those related to 
antimicrobial resistance. These processes are achieved thanks to mobile 
elements combined with resistance genes such as insertion sequences (IS), 
transposons, integrons, plasmids and resistance islands (RI). 
	  	  
 Insertion sequences and transposons 5.2.1.
IS are very small mobile DNA elements (< 2.5 Kb), encoding only the 
information needed for their mobilization. The mobilization is mediated by a 
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transposase and this coding region is flanked by two inverted repeats (IR) and 
two direct repeats (DR) generated after transposition (119). 
	  
Figure 8. ISAba1 sequence. 	  	  
IS are involved in antimicrobial resistance by three mechanisms: 
- Insertion of the IS upstream the gene, which can lead to its 
overexpression. For example ISAba1 upstream the blaOXA-51-like gene is known 
to increase resistance to carbapenems because it promotes the overexpression 
of the gene (120). Other IS such as ISAba2, ISAba3, ISAba4, ISAba10, 
ISAba16, ISAba18, ISAba125 and ISAba825 have been found upstream blaOXA-
23 and blaOXA-58 (108). 
- IS elements can also insert into a coding sequence and disrupt the gene. 
This is the case, for example, of ISAba1 inserted into the transcriptional 
regulator adeS which controls the expression of the AdeABC efflux pump, 
causing its overexpression (121). 
- The main mechanism of antimicrobial resistance mediated by IS is the 
mobilization of genes within the chromosome, between the chromosome and 
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plasmids, between different strains and even among bacteria from different 
genus.  
There are different mechanisms to mobilize gene cassettes, the simplest 
one is when the cassette is flanked by two IS, these IS act together and move 
the complete DNA sequence from one IS to another, these are called 
compound transposons. For example the blaOXA-23 gene flanked by two ISAba1 
in inverse or direct orientation, called Tn2006 and Tn2009 respectively. When 
there is just one IS, a mechanism called one-ended transposition can move the 
genes by using one of the ends of the IS working together with a sequence of 
certain similarity in the surroundings, this is a simple transposon, the blaOXA-23 
gene with an inverted ISAba1 upstream form Tn2008. Another way of 
mobilization is the one mediated by IS from the IS91 family (ISCR1 and ISCR2) 
by a rolling-circle replication mechanism (108). 
	  
Figure 9. Genetic structure of simple and compound transposons carrying blaOXA-23 in A. 
baumannii. 
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The genes tet(A) and tetR, encoding for a tetracycline efflux pump and its 
regulator, respectively, have also been found in Tn1721-like transposons that 
can be present in multiple copies in the bacterial chromosome (108). 
	  
Figure 10. Genetic structure of Tn1721.  
 
 Integrons 5.2.2.
Integrons are genetic structures that coordinate the site-specific 
integration of gene cassettes and regulate their expression. Integrons have a 
conserved region with three genes, attI, the specific recombination site; intI, 
integrase encoding gene and a promoter region, P1-P2; and a variable region 
where the resistance genes are located. Integrons are not mobile but together 
with IS elements or by homologous recombination they can spread to 
chromosomal locations, plasmids or to other strains. 
Integrons in A. baumannii are classified by the homology of their 
integrases; class 1 integrons normally encode aminoglycoside and 
sulphonamide resistance genes and genes conferring resistance to antiseptics, 
as well as β-lactams. Class 2 integrons are related to Tn7 and the diversity of 
the genes they can carry is smaller than class 1. Some of the genes confer 
resistance to aminoglycosides, chloramphenicol, or trimethoprim (108).  
 
INTRODUCTION  
 
	   	   	  51	  
 Resistance islands 5.2.3.
Large clusters of antimicrobial resistance genes together with genes 
conferring resistance to heavy metals have been found in the A. baumannii 
chromosome, and they are called resistance islands (RI). Mobile structures 
such as IS, transposons and integrons are part of RI. Usually these resistance 
islands are integrated in a specific site, disrupting the comM gene but other RI 
were found in other locations of the chromosome (108). Several RIs have been 
characterized up to now and they have been found to be related to the 
international clone (IC) of the strain, which provides further evidence of the 
independent evolution of the A. baumannii clonal lineages The first and largest 
RI in A. baumannii was found in the resistant strain AYE, it was called AbaR1 
and carried 45 antibiotic and heavy metals resistance genes in a 86 Kb 
structure (108, 122). Although, several RI with very diverse structures have 
been reported since then. 
 
 Plasmids in Acinetobacter baumannii 5.2.4.
Plasmids are extrachromosomal genetic material within the cell. Some of 
them exhibit a self-inducible transfer to new bacterial cells; this is called 
conjugation and it is part of the horizontal gene transfer (HGT) that is the 
movement of genetic material between different cells, which differs from the 
parent-daughter vertical transfer. Plasmids are capable of self-replication and 
they ensure their own survival in the bacterial cell with systems such as post-
segregational killing or partitioning systems, which can cause cellular death 
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(123).  
Conjugation is a process that takes place between two bacteria, the 
donor and the recipient, the donor carries plasmid encoding genes for 
multiplication and transfer proteins, and by the establishment of a channel 
connecting both cells, the replicated plasmid is able to transfer. Plasmids can 
also be non-transmissible or mobilizable, which means that they can only be 
transferred by cell division or by conjugative elements’ help. Plasmids also 
encode stability genes, including partitioning regulation systems (type I: parA, 
parB, parC) that contribute to the equal distribution of plasmids between 
daughter cells, or toxin-antitoxin systems, that are involved in vertical stability, 
which means that if the daughter cell does not contain the plasmid, the toxin 
kills the cell. The activity of this toxin-antitoxin system relies on the stability of 
both components, if the daughter cell does not inherit the plasmid, the antitoxin 
that is higly unstable is degraded while the toxin protein is very stable and kills 
the cell (123). 
Plasmids carry beneficial genes for the bacteria, for example virulence 
genes or acquired antimicrobial resistance determinants that are generally 
integrated in resistance cassettes related to translocation elements, that lead to 
an accumulation of resistance to multiple drugs. Multi-drug resistance encoding 
plasmids are often larger that 50 Kb and have a strict control for their 
replication, controlling their copy number and the stability when with another 
plasmid in the cell; plasmids with the same Rep (replication initiator proteins) 
cannot be in the same cell, this is known as plasmid incompatibility. 
Plasmids in Acinetobacter spp. have been described to be unique and 
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not related to those of other genera. Different groups of plasmids within A. 
baumannii have been described according to the nucleotide identity of their 
replicase genes; this method is called replicon-typing and the groups are 
represented by AbGR (124, 125). The plasmid replicase gene or replicon is the 
origin of replication of the DNA. Nineteen groups comprising twenty-seven 
replicase genes have been stablished (AbGR1-AbGR19) in order to classify A. 
baumannii plasmids, although some other replicons that cannot be grouped 
according to these groups have since then been found (126, 127).   
In A. baumannii very diverse plasmids can be found, ranging in size from 
2 Kb to more than 150 Kb. The larger plasmids normally carry more than one 
resistance gene, but up to now little is known about these plasmids (125, 128).  
Diverse plasmids have been described in the different A. baumannii ICs. 
For example, four different plasmids were found in two IC2 A. baumannii 
isolates from Malaysia; the smallest one was an 8.7 Kb plasmid with two 
replicons, a TonB-dependent receptor, involved in transmiting signals from the 
outside of the cell leading to transcriptional activation of target genes; a 
septicolysin encoding gene that is a cytolytic enzyme toward eukariotc cells and 
is involved in pathogenesis; and a Toxin-Antitoxin system. Other plasmids that 
were found in these two isolates were two very similar conjugative 70 Kb 
plasmids, encoding a tra locus, responsible for mating pair formation spans and 
plasmid mobilization, as well as genes for the T4SS, this secretion system is 
homologous to conjugation mechanism and is able to secrete or take up both 
proteins and DNA. The uptake of naked DNA from the environment is known as 
natural competence. The main difference among these two plasmids is that one 
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of them carries the blaOXA-23 and the isolate carrying this plasmid has another 
copy of the blaOXA-23 gene in the chromosome (129). An A. baumannii isolate 
belonging to IC1 contained three plasmids, a 8.7 Kb one carrying aadB 
conferring resistance to gentamicin, kanamycin and tobramycin; this 8.7 Kb 
plasmid was also found in IC2 along with a larger plasmid (200 Kb) carrying 
sul2, sulphonamide resistance gene, strAB, streptomycin resistance gene and a 
mercuric resistance operon (128). Different studies have reported large 
plasmids within IC7 A. baumannii isolates, all of them carrying the resistance 
genes sul2, strA and strB and the efflux pump encoding gene tetB (130, 131). 
The biggest group of small plasmids in A. baumannii comprises the Rep-
3 superfamily (repB). This replicon is sometimes accompanied by a conserved 
domain called repA, although it has no similarities to any known replicase; repB 
can also be on its own. This Rep-3 superfamily group of plasmids encode for 
Type II toxin-antitoxin systems, TonB-dependent receptors, septicolysin and 
Sel1-repeat protein, and some of them also encode MobL or MobA mobilization 
proteins, making them mobilizable by other self-transmissible plasmids. 
There is a group of very small enigmatic plasmids grouped in the Rep-1 
superfamily, they encode a rep gene and from two to five ORF of unknown 
function (132).  
Another plasmid group derived from the same ancestor plasmid has been 
described, these plasmids carry the aadB gene conferring resistance to 
aminoglycosides such as gentamicin, kanamycin and tobramycin; as well as 
mobilization proteins (MobA) and other hypothetical proteins (132). 
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5.3. Efflux pumps 
Efflux pumps play an important role in A. baumannii antimicrobial 
resistance as they can confer resistance to many different classes of antibiotics 
such as β-lactams, chloramphenicol, tetracycline, aminoglycosides and 
tigecycline, as well conferring resistance to antiseptics and disinfectants. Five 
super-families of chromosomally encoded efflux pumps have been associated 
with antimicrobial resistance in A. baumannii, ATP-Binding Cassette 
transporters (ABC), multi-drug and toxic compound extrusion (MATE), 
resistance-nodulation-cell division (RND), major facilitator superfamily (MFS) 
and small multi-drug resistance families (SMR) (133). The ABC family, MATE 
family, MFS family and SMR family are located on the inner membrane and all 
of them have a narrow substrate specificity, being able of transporting drugs 
from the cytosol into the periplasm, while the RND family are transmembrane 
proteins with a broad substrate specifity and they pump drugs from the 
periplasm out of the cell. These efflux pumps may be specific for one substrate 
or able to transport a wide range of substrates. 
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Figure 11. Efflux pumps involved in antimicrobial resistance in A. baumannii (134). 
 
 RND efflux systems  5.3.1.
AdeABC: it was the first RND system characterized in A. baumannii. It is 
encoded in an operon and when it is overexpressed, either by mutations in 
the adeRS genes, or by the insertion of ISAba1 in adeS, it confers 
resistance to aminoglycosides, β-lactams, fluoroquinolones, tetracyclines, 
tigecycline, macrolides, chloramphenicol and trimethoprim. In a study, this 
adeABC operon was found in 80% of A. baumannii isolates (133). 
AdeIJK: it was the second RND efflux system described in A. baumannii. 
This RND pump confers intrinsic resistance to β-lactams, fluoroquinolones, 
tetracycline, tigecycline, lincosamides, rifampin, chloramphenicol, 
cotrimoxazole, novobiocin and fusidic acid. This pump works in a 
synergistic way with AdeABC to eliminate some compounds (118). 
AdeFGH: it is encoded in an adeFGH operon, regulated by the upstream 
adeL and its overexpression confers high-level resistance to 
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fluoroquinolones, chloramphenicol, trimethoprim and clindamycin and some 
low level resistance to tetracyclines, tigecycline and sulfamethoxazole 
(133). 
AdeABC and AdeIJK are able, in addition to extrude other compounds 
such as detergents, biocides, antiseptics and dyes. 
 
 MFS family 5.3.2.
CraA: it confers resistance to chloramphenicol but it is still not known if it is 
constitutively or only after overexpression. The gene that encodes the pump 
structure is overexpressed in presence of NaCl (133). 
 
 MATE  5.3.3.
AbeM: the role of this pump is still hypothetical although it is known that it 
extrudes aminoglycosides, fluoroquinoloes, chloramphenicol, trimethoprim, 
ethidium bromide and dyes (133). 
 
 SMR  5.3.4.
AbeS: this pump confers low-level resistance to chloramphenicol, 
fluoroquinolones, erythromycin and novobiocin, as well as, dyes and 
detergents (133). 
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 ABC transporters 5.3.5.
MacB: this inner membrane transporter has been described in A. 
baumannii forming a transmembrane pump together with MacA, a 
membrane fusion protein, and TolC, an outer membrane protein that pumps 
out of the cell. Macrolides are one of its substrates (135).  
 
 Acquired efflux systems 5.3.6.
Several studies have reported the acquisition of efflux pumps by A. 
baumannii as being part of mobile structures such as plasmids, 
transposons or resistance islands. For example, the genes encoding for 
efflux pumps TetA (conferring resistance to tetracycline) and TetB 
(conferring resistance to tetracycline and minocycline) from the MFS have 
been found in plasmids in A. baumannii. Structural genes for MFS, CmlA 
and FloR, that confer resistance to chloramphenicol have been described 
within the resistance island AbaR1. Additionally, the gene qacE has been 
found in the same resistance island, it encodes a SMR efflux pump, which 
can confer resistance to quaternary ammonium compounds (133). 
 
5.4. Outer membrane proteins  
Porins are pores in the outer membrane that allow the passive diffusion 
of various compounds into the periplasm, some of which are involved in 
virulence, also play a role in antimicrobial resistance. Reduced expression of 
the porins, CarO, Omp22-33, Omp33-36, Omp37, Omp43, Omp44 and Omp47 
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are associated with carbapenem resistance. Reduced expression of OmpA is 
also involved in aztreonam, chloramphenicol and nalidixic acid resistance (118). 
 
5.5. Aminoglycoside modifying enzymes 
There are many genes encoding for aminoglycoside modifying enzymes 
(AMEs), which are the major aminoglycoside resistance mechanism; they are 
grouped into acetyltransferases (AACs), adenyltransferases (ANTs) and 
phosphotransferases (APHs). Some examples are AACs: AAC3, AAC(6’); 
ANTs: ANT(2”) or aadB, ANT(3”) or aadA1; and APHs: APH(3’) or aphA1 and 
APH(3”). The specificity of these enzymes normally confers resistance to only 
one or two aminoglycosides; they catalyse the modification of the 
aminoglycoside, inhibiting its capability to bind to the 30s ribosomal subunit and 
confering high-level resistance to gentamicin, tobramycin and amikacin (5, 118, 
136).  
 
5.6. Target modification  
The modification of the target site of an antimicrobial can lead to 
antimicrobial resistance as its action is impaired. For example, ribosomal 
modification by 16s rRNA methyltransferases (16s RMTases) which modifies 
the binding site of the antibiotic, is another mechanism of aminoglycoside 
resistance. Some of the 16s RMTases that have been described in A. 
baumannii are ArmA and RmtB (136). Mutations in the genes gyrA and parC 
confer quinolone resistance, as these mutations change the antibiotic binding 
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site. By the action of TetM binding to the ribosome, tetracycline resistance is 
also increased as TetM protects the ribosome and the drug is released from its 
binding site; loss of LPS, or addition of phospoethanolamine to LPS by the 
PmrABC system have also been described to decrease the susceptibility to 
many antibiotics such as polymixins (5, 118) 
 
6. EPIDEMIOLOGY OF Acinetobacter  spp. IN LATIN AMERICA 
6.1. A. baumannii 
A. baumannii has been defined as clonal in nature and eight major 
groups to classify the isolates have been identified and were termed 
International Clones (ICs) due to the fact that they are spread worldwide (IC1, 
IC2, IC3, IC4, IC5, IC6, IC7 and IC8). Although some of these clones have been 
reported in many parts of the world, published data suggests that the clones 
have originated in different locations and then they have spread to other places 
(3). A. baumannii isolates can persist in the hospital settings for  many years 
while acquiring multiple antimicrobial resistance determinants and then they can 
spread again and cause an outbreak (137). The presence of different 
international clones (ICs), such as IC4, IC5, and IC7 have been isolated in 
several Latin American countries, and this differs from the epidemiological 
situation found in Europe or North America, where the majority of the isolates 
belong to IC1, IC2 or IC3; with IC2 the most prevalent and widespread 
worldwide (3, 138). IC2 has been reported related to blaOXA-23-like 
carbapenemase gene, but this clone can acquire other OXAs, and OXA-23 is 
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foundin other ICs (139). But even though the situation is different, the incidence 
of carbapenem-resistant A. baumannii (CRAb) is also increasing in Latin 
America (3, 137, 140–142). The nonsusceptibility rates to ceftazidime (76%), 
ciprofloxacin (65%), gentamicin (72%), imipenem (53%) and meropenem (58%) 
of this pathogen in Latin America appear to be higher than in other parts of the 
world according to the PAHO report from 2014, however the results in this study 
might be skewed because of inaproppiate species identification which can lead 
to the inclusion of non-baumannii isolates that are normally less resistant to 
antimicrobials (143). 
The dissemination of these ICs is often associated with antibiotic 
resistance, especially resistance to carbapenems. The spread of these ICs 
mirrors the increase of circulating carbapenemase-encoding genes such as 
blaOXA-23 which has now been widely reported worldwide (137, 141, 144). In 
previous studies carried in Latin American countries the predominant 
carbapenem resistance determinant was blaOXA-58 but it has recently been 
replaced by blaOXA-23 (137, 145, 146).  
For example, IC4 (CC15P) has been described in a study comprising 
69.4% of the isolates between 2009-2011 in a Brazilian hospital, all these 
isolates carried the carbapenem-resistance gene blaOXA-23 (142). This IC has 
been also found in other Latin American countries such as Argentina and Chile, 
normally representing unrelated or sporadic cases (3). In the previously 
mentioned study, IC5 (CC79P) comprised just 10% of the isolates, it appears to 
be the most prevalent among other studies carried out in Latin American 
countries (147, 148). IC5 has been mainly isolated in North, Central and South 
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America and it received the name Pan-American clone because of this (3). On 
the other hand, IC7 (CC25P) has been reported worldwide and associated with 
diverse antimicrobial resistance determinants such as blaNDM-2, blaOXA-72, blaOXA-
58 and blaOXA-23 (3, 139, 149). In Latin America, this clone has been reported in 
hospitals in Brazil, Paraguay, Bolivia, Argentina, Colombia, Mexico and 
Venezuela (3, 141, 142). Two sporadic A. baumannii isolates belonging to IC5 
and IC7, respectively, have recently been isolated from neonates in a hospital in 
Brazil (150) while in Colombia most of the isolates recovered in a 2017 study 
belonged to CC636Ox (IC5) followed by CC110Ox (IC7) (151). 
Furthermore, there has been an increase of CRAb isolates from 27% in 
2006 to 76% in 2009 along with the high prevalence of this pathogen in Latin 
America, however Bolivia had the lowest resistance rates of 19% and 7% to 
imipenem and meropenem, respectively, but as the identification method is not 
always clear, the same problem of misidentification as previously mentioned 
can be faced (137). The increasing incidence of CRAb was confirmed in studies 
carried out in 2012 and 2015 in the hospitals of the city of Cochabamba, where 
carbapenem resistance was found to be 35% and 90%, respectively (145, 149). 
 
6.2. A. seifertii 
Acinetobacter seifertii is one of the more recently named members of the 
Acinetobacter calcoaceticus-Acinetobacter baumannii complex (50). The first 
two strains of this species were isolated from human clinical specimens (ulcer 
and blood) in Denmark in 1990-1991 and they were named Acinetobacter gen. 
sp. ‘close to 13TU’ (50, 51). A. seifertii has since been found in diverse clinical 
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samples mainly in countries in Southeast Asia and South America, and it has 
been also isolated from environmental samples both inside and outside the 
hospital (4, 50, 103, 104, 106). Although the clinical relevance of A. seifertii 
seems to be lower than that of other members of the complex, reports of its 
incidence causing infections have been published recently. In addition, some 
isolates were shown to have acquired antimicrobial resistance genes such as 
the plasmid encoded carbapenemase blaOXA-58, and it has even been reported 
to have acquired the A. baumannii intrinsic blaOXA-51 and can therefore make 
anti-infective therapy difficult (4, 79). 	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The objectives of this thesis were to: 
 
1.  Characterize the clinical Acinetobacter spp. isolates from the 
main hospitals of Cochabamba, Bolivia, Hospital Materno-Infantil 
and Hospital Viedma, and investigate their molecular 
epidemiology.  
 
2. Determine their resistance to antibiotics and the associated 
mechanisms conferring resistance to different groups of 
antibiotics. 
 
3. Investigate the structure of mobile genetic elements such as 
transposons, plasmids, or resistance islands that are responsible 
for the spread of the antimicrobial resistance determinants among 
isolates.  
 
4. Correctly identify Acinetobacter spp. isolates from Hospital 
Materno-Infantil and Hospital Viedma.
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MATERIALS AND METHODS 
1. Bacterial isolates 
Two independent groups of isolates were studied. A total of thirty-six A. 
baumannii isolates were collected between March 2014 and May 2015 at 
Hospital Materno-Infantil in Cochabamba, Bolivia. This 208-beds children 
hospital is a tertiary-care hospital with 14 beds in the intensive care unit. The 
isolates were first identified at the hospitals’ laboratories as Acinetobacter spp 
by phenotypic methods such as Gram-negative by Gram staining; non-
fermenter (K/K) by triple sugar iron agar; negative motility in brain heart infusion 
broth; negative oxidase, negative gelatin liquefaction, and negative hemolysis. 
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Table 3. A. baumannii Isolates recovered between March 2014 and May 2015 in Hospital 
Materno Infantil. 
Isolate Hosp.code Date Sex Age Sample Diagnostic 
MI1 287 03/14 F 5 d Blood Culture Sepsis 
MI2 247 03/14 - 3 d Respiratory Tract Preterm neonate 
MI3 243 04/14 M 1 m Respiratory Tract Neumonía neonatal 
MI4 296 04/14 M 10 d Blood Culture Preterm neonate Congenital syphilis 
MI5 275 04/14 M 11 d Catheter Preterm neonate Congenital syphilis 
MI6 275 04/14 M 4 d Blood Culture Gastroschisis 
MI8 200-2 04/14 F 4 d Blood Culture Sepsis 
MI9 295 04/14  4 d Blood Culture Sepsis MI11 287 06/14 F 7 d Blood Culture Preterm neonate 
MI12 286 06/14 F 13 d Blood Culture Pneumonia 
MI14 260 10/14 M 2 d Catheter Preterm neonate 
MI17 262 10/14 M 20 d Surgical wound Sepsis 
MI18 423 11/14 F 3 m Blood Culture Sepsis 
MI19 269 11/14 M 8 d Blood Culture Sepsis 
MI22 434 11/14 F 2 y Surgical wound Cerebral tumor 
MI23 7 11/14   Environmental Anesthesiology machine MI24 432 11/14 F 2 y Cerebrospinal fluid Cerebral tumor 
MI25 16 11/14   Environmental Stretcher MI26 268 11/14 M 6 d Cerebrospinal fluid Sepsis 
MI28 44 12/14 F 14 y Aspirate Pneumonia 
MI30 13 12/14 F 14 y Aspirate Pneumonia 
MI31 410 12/14 F 11 m Aspirate 
Uremic hemolytic 
syndrome 
MI33 424 12/14 F 11 m Peritoneal fluid 
Uremic hemolytic 
syndrome 
MI38 413 01/15 F 1 d Blood Culture Sepsis 
MI39 407 02/15 F 1 y Cerebrospinal fluid Meningitis 
MI41  02/15 M 2 y Abscess Abscess 
MI42  03/15 M 8 y Respiratory Tract Pneumonia 
MI44 406 04/15 M 1 m Respiratory Tract Pneumonia 
MI45 421 04/15 M 1 m Respiratory Tract Pneumonia 
MI47 423 04/15 M 2 y Respiratory Tract Acute respiratory infection 
MI50 412 04/15 - - Respiratory Tract Pneumonia 
MI51 46 05/15   Environmental Operating room tripod 
MI52 15 05/15 M 8 y Exudate Tissue infection 
MI53 33 05/15 F 10 y Catheter Sepsis 
MI54 3 05/15   Environmental Student’s hands 
MI59 8 - M 10 y Respiratory Tract Pneumonia 
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A total of ninety-eight isolates recovered between September 2015 and 
December 2016 from two geographically close hospitals, Hospital Materno 
Infantil and Hospital Viedma in the city of Cochabamba, Bolivia, were included 
in the study. These two hospitals have a combined total of 408 beds and 21 ICU 
beds. All isolates were previously identified by biochemical methods at the 
hospital clinical laboratories as previously stated. 
Table 4. A. baumannii isolates recovered between September 2015 and July 2016 in 
Hospital Materno Infantil. 
Isolate Hosp.  code Date Sex Age Sample Diagnostic 
MC1 421-269 09/15 M 9 m Catheter Sepsis 
MC2 26-268 10/15 M 9 y Endotracheal tube Myeloid leukemia 
MC3 14-386 10/15 F 28 y Tracheal Secretion Organophosphate poisoning 
MC4 200-24-501 10/15 F 33 y Retroculture Hysterectomy 
MC5 417-517 10/15 F 1 m Tracheal aspirate Bronchiolitis 
MC6 421-237 11/15 M 9 m Endotracheal tube Pericardial effusion 
MC7 35-481 11/15 F 35 y Tracheal Secretion Pulmonary fibrosis 
MC8 43-735 11/15 F 8 y Tracheal Secretion Tracheal infection 
MC9 363-830 01/16 M 7 m Abscesse Secretion Parapharyngeal abscess 
MC10 47-942 01/16 M 12 y Catheter Ileostomy 
MC12 25-299 02/16 M 13 y Pleural Tube Pleural effusion 
MC13 30-324 03/16 F 59 y Abscesse Secretion Abdominal abscess 
MC14 200-26-501 03/16 F 5 d Blood Culture Sepsis 
MC15 201-825 04/16 M 3 d Blood Culture Sepsis 
MC16 421-133 04/16 F 2 y Catheter Sepsis 
MC17 405-156 04/16 F 5 d Blood Culture Sepsis 
MC18 412-201 04/16 F 2 y Foley Catheter Sepsis 
MC19 413-202 04/16 F 2 y Blood Culture Sepsis 
MC21 5-849 05/16 M 8 y Tracheal Secretion Pneumonia 
MC22 236-21 07/16 F 43 y Bronchial Secretion Puerperium 
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Table 5.	  A. baumannii isolates recovered between January 2016 and December 2016 in 
Hospital Viedma.	  
Isolate Hosp.code Date Sex Age Sample Diagnostic 
MC23 226 01/16 M 71 y Urine Culture - 
MC24 271 01/16 M 28 y Surgical Wound Necrotizing fasciitis 
MC25 300 01/16 F 17 y Abdominal Secretion Septicemia 
MC27 758 02/16 F 76 y Pressure ulcer Traumatic brain injury 
MC29 866 02/16 F 51 y Urine Culture - 
MC30 863 02/16 M 37 y Knee-joint exudate Fracture 
MC31 928 02/16 M 19 y Catheter - 
MC32 1054 02/16 F 53 y Ulcer Infected ulcer 
MC33 1229 02/16 M 74 y Tracheal secretion Sepsis 
MC34 1330 02/16 F 30 y Tracheal secretion Burn 
MC35 1369 02/16 M 33 y Knee-joint exudate Pressure ulcer 
MC37 1371 02/16 M 33 y Knee-joint exudate Pressure ulcer 
MC38 1417 02/16 M 75 y Urine Culture - 
MC39 1614 03/16 M 75 y Urine Culture - 
MC40 1657 03/16 F 33 y Tracheal secretion Epidural hematoma 
MC41 1718 03/16 M 63 y Urine Culture - 
MC42 1735 03/16 M 76 y Tracheal secretion Traumatic brain injury 
MC43 1738 03/16 M 76 y Blood culture - 
MC44 1987 03/16 F 53 y Wound secretion Burn 
MC45 2053 03/16 M 65 y Bronchial aspirate Septic shock 
MC47 2071 03/16 M 40 y Tracheal secretion Hypovolemic shock 
MC48 2074 03/16 M 65 y Secretion Prostate cancer 
MC49 2079 03/16 M 37 y Tracheal secretion Craniotomy 
MC50 2082 03/16 M 65 y Tracheal secretion Sepsis 
MC51 2090 03/16 M 65 y Lumbosacral ulcer - 
MC52 2104 03/16 M 28 y Secretion Necrotizing fascitis 
MC53 79 04/16 M 20 y Wound secretion Wound 
MC54 155 04/16 F 61 y Ulcer Infected ulcer 
MC55 185 04/16 M 38 y Tracheal secretion Craniotomy 
MC56 235 04/16 M 38 y Dental Abscess Dental abscess 
MC57 542 04/16 M 62 y Tracheal secretion Pneumonia 
MC58 842 05/16 M 37 y Wound secretion Bone surgery 
MC59 1110 05/16 M 34 y Catheter - 
MC60 1131 05/16 F 75 y Catheter - 
MC61 1133 05/16 F 75 y Tracheal secretion Sepsis 
MC62 1154 05/16 F 34 y Tracheal secretion Sepsis 
MC63 1237 05/16 F 86 y Fluid (Bone tissue) Bone tissue infection 
MC64 1245 05/16 M 36 y Urine Cult - 
MC65 1319 05/16 F 17 y Tracheal secretion Tube exchange catheter 
MC66 1350 05/16 F 61 y Tracheal secretion Cerebellum tumor 
MC67 1783 06/16 M 76 y Urine Culture - 
MC68 1797 06/16 M 27 y Tracheal secretion Tube exchange catheter 
MC69 1826 06/16 F 86 y Wound secretion Tissue infection 
MC70 1955 06/16 F 41 y Fuid - 
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Table 5. Continued. 
MC71 87 07/16 M 66 y Exudate (leg) Osteomyelitis 
MC72 316 07/16 F 61 y Tracheal secretion Septic shock 
MC90 939 08/16 M 90 y Blood culture - 
MC79 1409 09/16 M 20 y Tracheal secretion Tube exchange catheter 
MC80 1642 09/16 F 90 y Exudate (leg) Infected ulcer 
MC81 1670 09/16 M 76 y Wound secretion Infected wound 
MC82 1798 09/16 M 75 y Secretion Septic arthritis 
MC83 1861 09/16 M 24 y Secretion Fasciitis 
MC84 1864 09/16 F 56 y Ulcer Pressure ulcer 
MC85 1886 09/16 F 82 y Secretion (tumor) Surgical wound 
MC86 1892 09/16 F 67 y Tracheal secretion - 
MC87 1901 09/16 M 83 y - Pneumonia 
MC88 1951 09/16 M 72 y Cervical abscess - 
MC89 1978 10/16 F 56 y Ulcer Infected ulcer 
MC73 138 10/16 F 56 y Ulcer Infected ulcer 
MC74 265 10/16 F 45 y Wound secretion Abscesse 
MC75 289 10/16 M 84 y Ulcer Septicemia 
MC76 383 10/16 M 52 y Tracheal secretion Tube exchange catheter 
MC78 485 10/16 M 63 y - Gastric cancer 
MC77 386 10/16 F 30 y Tracheal secretion Acute respiratory infection 
MC91 679 11/16 M 71 y Urine Cult Chronic kidney disease 
MC93 739 11/16 F 66 y Wound secretion Burn 
MC94 740 11/16 F 66 y Wound secretion Burn 
MC95 863 11/16 F 75 y Tracheal secretion Traumatic brain injury 
MC96 1000 11/16 F 41 y Tracheal secretion Meningoencephalitis 
MC98 1200 11/16 M 66 y Wound secretion Chronic kidney disease 
MC99 1307 11/16 F 70 y Tracheal secretion Traumatic brain injury 
MC100 1318 11/16 F 68 y Tracheal secretion Tube exchange catheter 
MC101 1349 11/16 M 71 y Blood culture Chronic kidney disease 
MC102 1428 11/16 M 63 y Ulcer Renal tumor 
MC103 1429 11/16 M 29 y Pleural Fluid - 
MC104 1481 12/16 F 52 y Wound secretion Cellulitis 
MC105 1620 12/16 M 66 y Diabetic Foot Diabetic Foot 
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2. Species identification 
All PCR based methods were performed using the Taq PCR Master Mix 
Kit (Qiagen) or the KAPA2G Fast HotStart ReadyMix PCR kit 
(KapaBiosystems). 
 
2.1. gyrB multiplex PCR 
The isolates were confirmed to be A. baumannii by gyrB multiplex PCR. 
gyrB is a conserved gene within Acinetobacter spp. but using the differences in 
its sequence among the different species, a multiplex PCR was designed in 
order to differentiate the following species: A. baumannii, A. pitti, A. 
nosocomialis and A. calcoaceticus (75, 76). 
 
2.2. Presence of blaOXA-51-like 
The presence of the blaOXA-51-like has been described to be an indicator of 
the isolates belonging to A. baumannii as this gene is intrinsic to this species 
(77). 
 
2.3. Semi-automated systems 
Semi-automated systems such as VITEK®2 7.01 with the GN ID card 
(bioMérieux) and MALDI-TOF MS, Bruker MALDI Biotyper®, Compass IVD 
software (Bruker Daltonik GmbH) with HCCA portioned matrix were used for 
species identification. 
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2.4. Whole genome sequencing 
Total DNA extraction was performed from an overnight culture of a single 
colony incubated in 10 mL Luria-Bertani broth at  37°C, using the MagAttract 
HMW DNA Kit (Qiagen) following the manufacturer’s instructions. Quality of the 
DNA was determined by UV spectrophotometry using a NanoDrop 
Spectrophotometer (Thermo Scientific) considering a ∼1.8 A260/280 ratio as 
good; DNA concentration was determined using a Qubit dsDNA HS assay 
system (Thermo Fisher Scientific).  
DNA concentration was diluted to 0.2 ng/µL in nuclease-free water 
(SIGMA) and sequencing libraries were prepared using the Nextera XT library 
prep kit (Illumina GmbH). Tagmentation of the samples was performed using 
the Nextera XT transposome, which fragments the DNA and adds adapter 
sequences to its ends in a program at 55°C for 5 min and then decreasing the 
temperature to 10°C. Once the samples were tagmented, a limited-cycle PCR 
(Table 10) was performed in order to add the indexes/barcodes to the 
sequences; a different combination of an i7 and an i5 index/barcode for each 
sample. The addition of different indexes/barcodes to each sample allows for 
multiplexing and the consequent identification of the sequences belonging to 
each sample. 
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Table 6. Limited-cycle PCR for indexing 
Time Temperature  
3 minutes 72°C  
30 seconds 95°C  
10 seconds 95°C 
12 cycles 30 seconds 55°C 
30 seconds 72°C 
5 minutes 72°C  
Hold 10°C  
 
 
AMPure XP beads were used to purify the PCR products, a size selection 
is carried out in the library DNA, removing the very short DNA fragments in the 
library with two ethanol washings as well as primers, DNA templates and all the 
components that are no further required. After the cleanup, a normalization step 
was performed in order to ensure all libraries are equally represented. As the 
final step, prior to starting the sequencing, equal volumes of the normalized 
libraries were combined into a pooled sample, diluted in hybridization buffer and 
denaturated by heating. The pooled library was loaded into the reagent 
cartridge together with a PhiX control and MiSeq sequencer for a 250bp paired-
end sequencing run on an Illumina MiSeq sequencer. 
Sequencing quality had to fulfill the manufacturer’s minimum 
specifications. The resulting FASTQ files containing paired reads were de novo 
assembled with the Velvet 1.1.04 assembler using the Ridom SeqSphere+ v.3.0 
software (152) and SPAdes 3.9 (https://cge.cbs.dtu.dk/services/SPAdes/) (153).  
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Further analysis was performed in some isolates. 
- The CGE web-tools SpeciesFinder 1.2 (154), based on the complete 16s 
rRNA gene for species identification, and KmerFinder 2.0 (154, 155), that 
evaluates the number of co-occurring k-mers (strings of k nucleotides in DNA 
sequence data) were used (https://cge.cbs.dtu.dk/services/). 
- Multi locus sequence analysis (MLSA) using CLUSTAL 2.1 was performed; the 
concatenated sequences of the seven housekeeping genes used for the 
Pasteur MLST scheme were compared to those of forty-three reference strains 
(seven A.  calcoaceticus, eighteen A. baumannii, six A. nosocomialis, ten A. 
pittii, two Acinetobacter genomic species “between 1 and 3”) and fifteen A. 
seifertii strains used by Nemec et al to describe the species (50).  
- The digital DNA–DNA hybridization (dDDH) parameter was calculated 
between the three studied strains and the type strains, A. baumannii CIP 70.34 
T, A. calcoaceticus CIP 81.8T, A. dijkshoorniae JVAP01T, A. nosocomialis NIPH 
2119T, A. pittii CIP 70.29T and A. seifertii NIPH 973T using the GGDC 2.1 
(http://ggdc.dsmz.de) program, with the recommended parameters and 
threshold value for species, 70%.  
- In addition, JSpeciesWS webserver (http://jspecies.ribohost.com/jspeciesws/) 
was used to determine the average nucleotide identity (ANI) based on BLAST+ 
(ANIb) for species identification using the complete genomes and comparing 
them to the type strains A. baumannii CIP 70.34T, A. calcoaceticus CIP 81.8T, 
A. dijkshoorniae JVAP01T, A. nosocomialis NIPH 2119T, A. pittii CIP 70.29T and 
A. seifertii NIPH 973T. A cut-off at 95% was used.  
 MATERIALS AND METHODS 	  
	   	   	  76	  
3. Identification of antibiotic resistance genes  
3.1. Molecular determination of carbapenemases 
A multiplex PCR was  performed to detect the presence of genes 
encoding blaOXA carbapenemases (blaOXA-51-like, blaOXA-23-like, blaOXA-58-like, blaOXA-
40-like, blaOXA-143-like and blaOXA-235-like) (156–158).  
The presence of metallo-β-lactamases (class B) was determined either 
by single PCR for the following genes: blaVIM, blaGIM, blaSPM-1 and blaIMP 
following previously established protocols (156, 157, 159) or together with some 
blaOXA carbapenemases by using two in-house multiplex PCRs. The first 
multiplex PCR included the following genes: VIM, KPC, blaOXA-40-like, NDM, 
blaOXA-48-like and blaOXA-23, while IMI, blaOXA-58-like, GES, GIM, IMP and ISAba1-
blaOXA-51-like were screened by a second multiplex PCR.  
 
3.2. Detection of ISAba1 upstream blaOXA-23-like 
The presence of the ISAba1 insertion upstream of blaOXA-23 was 
determined by PCR mapping and sequencing of PCR products as previously 
described (120). 
The PCR products were purified using GeneJet™ PCR Purification Kit 
(ThermoFisher Scientific) according to the manufacturer’s recommendations 
and then sequenced through an external resource (Macrogen Inc). 
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3.3. Phenotypic determination of class D and B β-lactamases 
The Modified Hodge Test for detection of class D-carbapenemase-
producing strains and the Hodge Test Imipenem-EDTA Double-Disk Synergy 
Test for the detection of metallo-β-lactamases were used (160). 
 
3.4. Molecular determination of aminoglycoside resistance 
Detection of genes encoding aminoglycoside-modifying enzymes ant(2”)-
Ia, aac(3)-IIa, aph(3’)-Ia, aac(3)-Ia, aph(3’)-VIa, aac(6’)-Ih, aac(6’)-Ib/cr and 
aac(6’)-IIa, and the 16 rRNA methylases armA, rmtB and rmtC was performed 
by PCR as previously described (161–166). 
 
4. Resistome by WGS 
The assembled genomes of all sequenced isolates were used to identify 
the acquired resistome by using ResFinder 2.1 
(https://cge.cbs.dtu.dk/services/ResFinder/), a web-based tool from CGE 
(Centre for Genomic Epidemiology). It identifies the acquired antibiotic-
resistance genes in the genome by using BLAST (167). Same results were 
obtained by using The Comprehensive Antibiotic Resistance Database (CARD) 
(168). 
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5. Antimicrobial susceptibility 
5.1. Method 1. Disk diffusion 
 Antibiotic susceptibility testing against 15 antibiotics was performed by 
disk diffusion on Mueller-Hinton agar: amikacin (30 µg), ampicillin-sulbactam 
(20 µg), cefepime (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), ceftriaxone 
(30 µg), ciprofloxacin (5 µg), doxycycline (30 µg), gentamicin (10 µg), imipenem 
(10 µg), meropenem (10 µg), piperacillin-tazobactam (110 µg), tetracycline (30 
µg), tobramicin (10 µg) and trimetoprim-sulphametoxazole (25 µg). Etests® 
(bioMérieux) were used to test colistin susceptibility (Etest 0.016-256 µg). This 
method is performed inoculating a Mueller-Hinton agar plate with a 0.5 
McFarland inoculum of the isolate in NaCl by using a sterile cotton swab. Then, 
the antimicrobial disks were applied to the surface of the inoculated plate and 
the incubation is performed at 35±1ºC in air for 16-20 h. After incubation the 
inhibition zone can be measured and checked in the breakpoint tables (116). 
Quality control strains were used to check the test performance, for example 
Escherichia coli ATCC® 25922™, Pseudomonas aeruginosa ATCC® 27853™ 
or Staphylococcus aureus ATCC® 29213™. The results were interpreted 
according to the clinical breakpoints recommended by EUCAST (116).  
 
5.2. Method 2. Agar dilution 
Antimicrobial susceptibility testing for some of the isolates was performed 
by agar dilution method according to the EUCAST guidelines and breakpoints 
(116, 169). Minimum inhibitory concentrations (MICs) were evaluated for 
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ciprofloxacin, colistin, gentamicin, imipenem, meropenem, and tigecycline. 
Stock solutions of the powder of tested antimicrobials are daily prepared 
accordingly to the following instructions. 
Volume of Solvent (mL)= Weight of powder (mg) x Potency of powder (mg/g) 
Concentration (mg/L) 
 
For most of the antimicrobials water is the solvent. Alternative solvents 
include phosphate buffer 0.01 M pH 7.2 for imipenem. Mueller-Hinton agar 
plates with different antimicrobial concentration (512-0.04 mg/L) were 
inoculated with a 0.5 McFarland standard from each isolate. The plates were 
incubated at 35-37ºC in air for 18 h. The MICs were determined as the lowest 
concentration plate in which there is no growth of the isolate. The EUCAST 
tigecycline MIC breakpoint for Enterobacteriaceae was used as no MIC 
breakpoints are available for A. baumannii. The reference strains  Escherichia 
coli ATCC® 25922™, Pseudomonas aeruginosa ATCC® 27853™ and 
Staphylococcus aureus subsp. aureus Rosenbach ATCC® 29213™ were used 
as control strains (169). The experiments were repeated three times for all the 
isolates. 
 
5.3. Method 3. Broth microdilution 
Broth microdilution was used in order to analyze colistin MICs, according 
to EUCAST recommendations. MICRONAUT-S microplates (MERLIN 
Diagnostika GmbH)  were used for this purpose. This microplates have 
lyophylized antibiotic and the principle is based on rehydratation with a 
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standarized bacteria suspension. A bacterial suspension 0.5 McFarland was 
prepared in NaCl 0.9% and 50 µL of this suspension were inoculated in 11 mL 
Mueller-Hinton broth. Inoculation of the plates was done with 100 µL of the 
bacterial suspension in Mueller-Hinton broth. The plates were covered and 
incubated at 35-37ºC in air for 24 h. Colistin MICs were interpreted according to 
EUCAST breakpoints. The reference strains  Escherichia coli ATCC® 25922™, 
and Pseudomonas aeruginosa ATCC® 27853™ were used as control strains. 
 
6. Biofilm formation experiments 
Biofilm formation was assessed as described by O’Toole (170) with 
some modifications.  Biofilms were developed in 24 well plates (Nunc, Thermo 
Fisher Scientific). Overnight cultures of bacteria were adjusted to an optical 
density of 0.2 at 600 nm; one hundred microliters were placed in each well 
containing 900 μL of M63 medium (minimal salts medium) supplemented with 
casamino acids (0.5% w/v) and incubated 24 h at 37°C. Planktonic cells were 
removed by taking out the medium (using a pipette) and the wells containing 
biofilms were rinsed three times with distilled water and air dried for 
approximately 20 min. The remaining adherent bacteria were stained with 1 
mL/well of 0.7% crystal violet (wt/vol) solution (Sigma-Aldrich) for 12 min. 
Excess stain was removed by three washes with distilled water. Crystal violet-
stained biofilm was solubilized in 1 mL of 33% acetic acid (vol/vol), and the 
plates were incubated at RT in an orbital shaker for 1 min at 400 rpm and the 
amount of dye (proportional to the density of adherent cells) was determined at 
MATERIALS AND METHODS  
 
	   	   	  81	  
620 nm using a microplate reader (Infinite® 200 PRO, Tecan). Results were 
corrected for background staining by subtracting the value for crystal violet 
bound to uninoculated control wells. The biofilm assay was performed 
independently four times. 
 
7. Molecular typing and analysis of the molecular epidemiology 
7.1. Method 1. Pulsed Field Gel Electrophoresis (PFGE) 
Plugs of genomic DNA were prepared from an overnight Luria-Bertani 
broth culture. The cultures were washed with saline solution and adjusted to a 
0.8-1 absorbance at 600 nm. 500 µL of the solution were mixed with 500 µL 2% 
agarose for plugs in TE.  
Once the plugs were solid, cell lysis was performed (Apendix 2).  
The plugs were incubated for 5 hours at 37°C. Then the plugs were 
washed with TE. This was followed by a proteinase K digestion (Apendix 2) at 
56°C overnight. 
After proteinase K digestion, the plugs were washed ten times with TE at 
50°C and digested with ApaI (30 U/µL) overnight at 37°C. The restricted 
fragments were separated on 1% Pulsed Field Certified™ Agarose (Bio-Rad) 
gels in 0.5x TBE (Tris-borate-EDTA) buffer using a CHEF-DR II system (Bio-
Rad) for 18.5 h at 14°C with 5-20 s of linear ramping at 6 V/cm. DNA 
fingerprintings were analyzed using the Fingerprinting II software package (Bio-
Rad) using the band-based Dice coefficient. The band tolerance and 
 MATERIALS AND METHODS 	  
	   	   	  82	  
optimization were both set at 1.5%. The threshold level for similarity was set as 
≥87% to assume clonal relatedness. 
 
7.2. Method 2. Whole Genome Sequencing, WGS 
 cgMLST 7.2.1.
A core-genome multi locus sequence typing (cgMLST) scheme was 
defined for A. baumannii using the Ridom SeqSphere+ v.3.0 software using A. 
baumannii ACICU as reference genome. The resulting core-genome of 2390 
alleles was used to investigate their molecular epidemiology (94). A minimum 
spanning tree based on the core-genome of 2390 alleles was generated using 
Ridom SeqSphere+ ignoring the missing values. Results of the cgMLST were 
also used to cluster the isolates into the different ICs using in-house reference 
strains (94). 
 
 blaOXA-51-like 7.2.2.
The blaOXA-51 variant has been described to be related to the ICs (140), 
and the blaOXA-51 variants in this study were used, as well, as another evidence 
to classify the isolates into the ICs. 
 
7.3. Method 3. Multi-locus sequence typing (MLST) 
 MLST by Sanger sequencing 7.3.1.
MLST was performed on selected isolates representing all the pulsotypes 
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as according to the Oxford scheme with the primers described in Apendix 1 (90, 
171). The PCR products of the amplified genes were purified by using 
GeneJet™ PCR Purification Kit (ThermoFisher Scientific) according to the 
manufacturer’s recommendations and sequenced thorugh an external resource 
(Macrogen Inc.). 
 Use of the PubMLST database allowed to identify the isolates and 
assign the new alleles and STs (https://pubmlst.org/abaumannii/). 
 
 MLST by WGS 7.3.2.
The assembled genomes of the sequenced isolates were used to 
determine the traditional seven loci MLST from both the Oxford and Pasteur 
Schemes (90, 91). The online database PubMLST was used as explained 
above (90, 91).   
 
 Molecular epidemiology by MLST 7.3.3.
eBURST software (http://eburst.mlst.net/) was used to analyze the 
sequence types (STs) and the relationship among them (171).  
The Pasteur Scheme STs helped to elucidate the International Clone that 
the isolates belonged to (92). 
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8. Determination of chromosome or plasmid encoded antimicrobial 
resistance 
8.1. Plasmid characterisation 
Plasmid DNA was extracted using a commercial kit (Plasmid Midi Kit, 
Qiagen) following the manufacturers instructions. Plasmid content was analyzed 
by electrophoresis on 0.7% agarose gels in 0.5x TBE buffer and plasmid size 
was determined by comparison to plasmid DNA extracted from the type strains 
E. coli NCTC 50193 (CECT678) and NCTC 59192 (CECT679) carrying 
plasmids ranging in size from 2 Kb to 154 Kb. 
 
8.2. S1-PFGE 
S1 nuclease-pulse field gel electrophoresis (S1-PFGE) and Southern blot 
hybridization were perfomed to determine the plasmid size and the 
plasmid/chromosomal location of blaOXA-23 and strA.  
Overnight cultures in 10 mL LB broth were used to prepare a bacterial 
suspension in cell suspension buffer (CSB). 
 300 µL of the bacterial suspension were mixed with 15 µL Proteinase K 
and incubated 10 min at 56°C. After that, bacterial suspensions were mixed with 
1% SeaKem Gold Agarose prepared in TE buffer with 1% SDS (sodium dodecyl 
sulfate) and plugs were made. 
 Once the plugs were prepared, they were incubated in Cell lysis buffer 
(CLB) with 25 µL Proteinase K in the waterbath during 3 h at 56°C.  
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Two water washings (10 min with 500 µL sterile water at 56°C) and three 
TE washings (15 min with 500 µL sterile TE at 56°C) were carried out. Total 
bacterial DNA embebded in agarose plugs were digested with 50U of S1 
nuclease (Thermo Fisher Scientific), that linearizes plasmids, and incubated at 
37°C for 45 minutes. The restriction digestion was stopped with 2 µL 0.5 M 
EDTA pH 8.0 at 70°C for 10 min and the resulting fragments were subsequently 
separated in a 1% PFGE agarose gel using a CHEF-DR II system (Bio-Rad). 
The PFGE conditions were  17 hours at 6 V/cm and 14°C, inital and final pulses 
were conducted at  4 and 16 s, respectively. The gel was stained with a 3 
mg/mL ethidium bromide solution.  
 
8.3. S1-PFGE and I-CeuI-PFGE 
Total DNA plugs were prepared following the protocol explained in 6.1.1., 
and digested with 10U of S1 enzyme (Thermo Fisher Scientific) at 37ºC for 45 
minutes. The resulting fragments were visualized on 1% Pulsed Field 
Certified™ Agarose (Bio-Rad) gels by PFGE using ramping of 5-20 s at 14ºC 
for 20 hours.  
To determine plasmid location of blaOXA-23, total DNA plugs were digested 
with I-CeuI endonuclease at 37°C O/N and the resulting fragments were 
separated by PFGE on 1% Pulsed Field Certified™ Agarose (Bio-Rad) gels in 
0.5x TBE buffer under the following conditions: temperature, 14°C; voltage, 6 
V/cm; and switch angle, 120°, with one linear switch ramp of 5 to 125 s for 22 h.  
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8.4. Southern Blot and hybridization 
DNA from the PFGE gels was transferred to a Hybond-N membrane 
(Sigma-Aldrich) by capillary transfer followed by hybridization with digoxigenin 
(DIG)-labeled specific probes (Roche) for blaOXA-23-like and strA. Chromosomal 
location was shown by colocalization with the blaOXA-51-like probe. 
The gel was subjected to a depurination step with 0.25 M HCl for 10-20 
min and then rinsed with sterile nanopure water. Then the DNA was twice 
denaturized in a denaturation solution for 15 min and then rinsed with sterile 
nanopure water. 
Consequently, it was submerged in neutralization solution for 15 min, and 
then the solution was changed for another 15 min. 
The gel was equilibrated for 10 min in 20x SSC. And a construction of 
Whatman® 3MM paper (Merck) soaking into 20x SSC, gel, Hybond-N 
membrane (Sigma-Aldrich), Whatman® 3MM paper (Merck), 9 cm of absorbent 
paper with a metalic lid and a weight on top was built. The construction was left 
overnight in order to obtain the migration of the DNA from the gel to the  
Hybond-N membrane. DNA was crosslinked to the membrane using a UV 
transilluminator and then the membrane was dried for at least 2 h. 
When the membrane is dry, proceed with the prehibridization. Roll the 
membrane into a net and introduce it in a glass tube with 10 mL/100 cm2 
hybridization buffer and place it in the hybridization oven at 42°C for 3.5 h. 
For the hybridization, a hybridization solution was prepared. Prewarm the 
hybridization buffer to 42°C. Take 45 µL of hybridization buffer and add the 
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probe, boil at 80°C for 5 min. Add the probe to the prewarmed hybridization 
buffer (5 µL probe/30 mL buffer). Add the hybridization solution to the tube 
containing the membrane and incubate overnight at 42°C in the hybridization 
oven. 
Two washings (15 min) with 200 mL of low stringency buffer and two 
washings (15 min) with 200 mL prewarmed (68°C) high stringency buffer were 
performed.  
Signal detection was performed according to manufacturer’s instructions 
using CDP-Star® ready-to-use (Roche) chemiluminescent substrate by 
autoradiography on a X-ray film (GE Healthcare). 
 
8.5. Plasmid analysis and scaffolding 
 PCR-based gap closure 8.5.1.
By using the resistome, S1-PFGE and Southern blot data, plasmid 
analysis was performed in three isolates belonging to different international 
clones; IC4, IC5 and IC7.  
S1-PFGE allows to assess the plasmids size and by hybridization, the 
plasmidic or chromosomal location of the resistance genes. Chromosomal 
location can be demonstrated by co-localization with chromosomal gene 
markers. 
Contigs of the WGS carrying resistance genes were examined together  
with other contigs of the de novo assembled genome. Plasmid assemblies and 
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predicted gaps were further confirmed using PCR-based gap closure. The 
contigs of interest were checked out for overlaps with others, this analysis 
allowed for a preliminary organization of the contigs which was further 
confirmed by designing specific primer pairs where overlaps were found and 
analyzing the obtained amplicons. 
	  
Figure 12. Some nodes of MC1 assembly and some primers designed for the 
hypothetical nodes of a plasmid. 	  
As a further confirmation of the plasmid scaffold, MinION long-read 
sequencing was performed. 
 
 MinION 8.5.2.
Oxford Nanopore Technologies (ONT) MinION long-read sequencer was 
used in order to obtain longer reads and confirm the plasmid structure.  
DNA extraction was performed using the Genomic-tip 100/G kit (Qiagen) 
from 2.5 mL overnight cultures in Luria-Bertani according to manufacturer’s 
specifications. The DNA was eluted in 300 μL TE buffer at 55°C for 1.30 h.  
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DNA concentration was measured with NanoDrop™ 2000/2000c 
and Qubit® 2.0 Fluorometer. 
 
Table 7. DNA concentration using Qubit® 2.0 
Fluorometer for MinION sequencing. 
Isolate DNA concentration 
MC1 180.8 ng/μL 
MC23 64.4 ng/μL 
MC75 58.8 ng/μL 
 
Library preparation was carried out according to manufacturer’s 
indications using a combination of Native Barcoding Kit 1D and Ligation 
Sequencing Kit 1D; EXP-NBD103 and SQK-LSK108 respectively. 
1-1.5 µg DNA were repaired using NEBNext® FFPE DNA Repair Mix 
(New England BioLabs) in order to improve the read lenght. End-repair and dA-
tailing of fragmented DNA was performed by NEBNext End repair/dA-tailing 
Module (New England BioLabs), to achieve an aim of 700 ng repaired DNA. 
Subsequently, ligation of the barcodes (Native Barcoding Kit 1D) was perfomed 
using Blunt/TA Ligase Master Mix (New England BioLabs) using 500 ng of each 
sample DNA. After barcoding, equimolar amounts of each sample were pooled 
to obtain in total 700 ng DNA in 50 µL nuclease-free water. The pooled DNA 
went through adapter ligation with the Barcode Adapter Mix and then it was 
loaded in a R9.4 flowcell (FLOMIN 106). MinION sequencer was run for 
approximately 19 hours. 
 MATERIALS AND METHODS 	  
	   	   	  90	  
The tool Albacore was used for demultiplexing the reads which were later 
used to perform the Canu assembly. Another assembly was made with 
hybridSpades, that combines both long and short reads from MinION and 
MiSeq, respectively. 
 Plasmid annotation and visualization 8.5.3.
First, ORFfinder (NCBI) (https://www.ncbi.nlm.nih.gov/orffinder/) was 
used in order to predict the open reading frames (ORF) in the plasmid 
sequences, it uses an algorithm which looks for a start codon (ATG and 
alternative initiation codons), followed by a protein encoding sequence (longer 
than 75 nt) and a stop codon. Consequently, putative gene function 
assignments were assigned with amino acid sequences using BLASTp (NCBI) 
and the non-redundant protein sequences database (NCBI). 
A second functional annotation of the genomes was performed using the 
online tool Rapid Annotation Subsystem Technology (RAST) (172); this server 
uses two different approaches to generate gene function: subsystem-based 
inferences rely on the recognition of functional variants of subsystems, which 
are defined as a set of functional roles and protein families; while other 
approaches are used for the nonsubsystem-based assertions, for example 
identification of tRNA and rRNA encoding genes using tRNAscan-SE and 
search_for_rnas, respectively. 
Consequently, the tool SnapGene Viewer (GSL Biotech) was used in 
order to obtain a circular diagram of the plasmids. The resulting diagrams were 
manually curated. 
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1. High Prevalence of Extensively Drug-Resistant 
Acinetobacter baumannii at a Children Hospital in Bolivia. 
 
RESULTS 
1. Bacterial isolates 
Thirty-six isolates recovered between March 2014 and May 2015 in 
Hospital Materno Infantil were confirmed as A. baumannii by the presence of 
blaOXA-51-like. 
 
2. Analysis of the cases 
Of the 36 A. baumannii isolates, fifteen (41.7%) were isolated from male 
patients and fourteen (38.9%) from female patients; four of them (11.1%) were 
from hospital environmental samples and for three of them (8.3%) the sex of the 
patient was not given. 
The patients (n=32) were grouped according to age in five groups, ≤1 
month [n=17, 53%]; >1 month ≤ 1 year [n=4, 12.4%]; >1 year ≤5 years [n=4, 
12.4%] and >5 years [n=6, 18.7%]. For one of the patients the age could not be 
precisely determined. 
The isolates were recovered from different sources: blood cultures (n=10, 
31.3%), respiratory samples (n=11, 34.4%), catheter (n=3, 9.4%), cerebrospinal 
fluid (n=3, 9.4%), surgical wound (n=2, 6.3%), abscess (n=1 3.1%), exudate 
(n=1, 3.1%) and peritoneal fluid (n=1, 3.1%). 
RESULTS AND DISCUSSION 	  	  
	   	   	  93	  
The most prevalent diagnostics were pneumonia (n=10, 31.3%) and 
septicaemia (n=9, 28.1%). There were other infections such as meningitis 
(n=1), skin and soft tissue infections (n=2), hemolytic uremic syndrome (n=2) or 
congenital syphilis (n=2).  
 
3. Susceptibility of A. baumannii isolates to antibiotics and mechanisms 
of resistance 
Antimicrobial susceptibility testing was performed by disk diffusion 
method and Etest® for colistin. 
The susceptibility and resistance rates to the different antibiotics can be 
seen in Figure 13. The majority of the isolates (n=30, 80.6%) were extensively-
drug resistant (XDR) and 8.3% (n=3) were multidrug-resistant (MDR) following 
the criteria of Magiorakos et al (173).  
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Figure 23. A. baumannii susceptibility-resistance rates. The dark bars indicate the 
percentage of resistant isolates and the light bars the susceptible isolates. The numbers 
within the bars represent the number of isolates in each category. 
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 All the carbapenem-resistant isolates carried the blaOXA-23-like gene 
as determined by blaOXA multiplex PCR, while in those isolates susceptible to 
carbapenems it was not present. Only the carbapenem resistant isolates gave a 
positive result for the Hodge Test. The aac(3)-IIa gene was present in all the 
aminoglycoside-resistant A. baumannii isolates (86.1%) but not in the 
aminoglycoside-susceptible ones. No other acquired class D or B β-lactamase 
genes, or aminoglycoside resistance encoding genes were detected by PCR. 
 
4. Molecular typing methods 
 Molecular epidemiology of the isolates was evaluated by ApaI-PFGE 
(Figure 14, Figure 15). The majority of the isolates were grouped into two 
predominant pulsotypes named E (n=10) and F (n=15). These pulsotypes had 
subclonal variants that differed by up to six bands, two within pulsotype E (E1-
E2) and six within pulsotype F (F1-F6). Nine isolates were considered sporadic 
strains because they were singletons and were isolated one or two times during 
all the study period. Two environmental isolates were non-typeable (NT) by 
using PFGE despite the experiment being repeated three times, no bands were 
obtained, ApaI was not able to cut the isolates DNA. 
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MLST according to the Oxford scheme was performed by Sanger 
secuencing, and eBURST was used in order to analyze the clonal relatedness. 
The isolates of the two predominant clones were single locus variants (SLV) of 
the clonal complex CC110 (Table 8) which belongs to the international clone 7 
(IC7), and differ only in the gpi allele with the exception of the double locus 
variant (DLV) ST1521. Five of the unrelated sporadic strains as determined by 
PFGE were also SLV of CC110 (STs 1489, 1518 and 1522). The rest of the 
isolates were assigned to ST1482, an SLV of CC741, and ST1531 and ST1532 
that are DLV of the same CC. 
 
 M    MI22  MI28  MI38   MI1   MI4   MI47  MI24  MI39  MI44  MI9  MI11  MI54  MI14  M 
Figure 14. ApaI PFGE of thirteen A. baumannii isolates. M, marker. Isolate and 
pulsotype. 
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Table 8. STs and CC of the isolates according to the Oxford 
scheme. 
Clone 
(n of 
isolates) 
ST CC gltA gyrB gdhB recA cpn60 gpi rpoD 
A (3) ST1489 CC110 (IC7) 1 15 2 28 1 283 32 
B (1) ST1532 CC741 21 35 2 28 107 302 4 
C (2) ST1482 ST1532 CC741 
21 
21 
35 
35 
2 
2 
28 
28 
1 
107 
175 
302 
4 
4 
D (1) ST1531 CC741 21 35 2 28 107 25 4 
E (10) ST1518 ST1521 
CC110 
(IC7) 
1 
1 
15 
15 
2 
2 
28 
43 
1 
1 
299 
102 
32 
32 
F (15) 
ST1489 
ST490 
ST1518 
CC110 
(IC7) 
1 
1 
15 
15 
2 
2 
28 
28 
1 
1 
283 
102 
32 
32 
G (2) ST1522 ST1518 
CC110 
(IC7) 
1 
1 
15 
15 
21 
2 
28 
28 
1 
2 
102 
299 
32 
32 
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5. Plasmid characterization 
In order to analyze plasmids, S1-PFGE was used; this analysis showed 
an ~180 Kb plasmid in 30 isolates, while one isolate also had an additional 
plasmid of ~39 Kb, two isolates carried two plasmids of ~100 Kb and ~80 Kb, 
and no plasmids were found in four isolates. 
 
6. Genetic context of blaOXA-23-like gene 
PCR-mapping of the blaOXA-23 genetic environment was performed in the 
32 strains harboring this gene. In 29 strains a highly similar structure (99%) to a 
previously described Tn2008 (LN877214.1) was revealed. 
In order to determine whether the blaOXA-23-like gene was located on the 
chromosome or a plasmid, digestion with I-CeuI and hybridization with a blaOXA-
23 probe were carried out. By Southern blotting, a positive signal was detected 
for the I-CeuI digested DNA hybridized with a specific blaOXA-23 probe, indicating 
a chromosomal location of the blaOXA-23 encoding gene. 
 
7. Biofilm formation 
Varying degrees of biofilm production were demonstrated among all the 
strains. It was observed that stronger biofilm-producers were isolated from the 
hospital environment (MI51, MI54, MI25 and MI23); catheter (MI14), blood 
(MI18) and CSF (MI24), and all of them, with the exception of MI24, were part of 
the sporadic strains (Figure 16). The isolates that clustered in the two 
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predominant pulsotypes E and F did not produce high levels of biofilm. The 
lowest levels of biofilm production were found in isolates belonging to pulsotype 
G, which were isolated from blood cultures. 
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DISCUSSION  
In this study the clonal relatedness and antmicrobial resistance profiles of 
A. baumannii from a Bolivian children hospital have been analyzed. The 
microbiology laboratory service in this hospital was established in 2014, and 
this is the first survey they have investigated in depth. The majority of the 
isolates were clustered in two pulsotypes, both of which are SLVs of CC110 that 
belongs to IC7 (92), which is one of the endemic ICs in Latin America (174). It is 
difficult to establish a connection between pulsotypes and sequence types 
because the same ST can be present in different pulsotypes. This can be due to 
the fact that MLST lacks the resolution of PFGE, in addition genomic 
rearrangements that will not necessarily change the ST will have an impact in 
the band pattern of the PFGE (92, 175). The presence of blaOXA-23-like in 88.9% 
of the isolates (in related and unrelated clones) matches the situation in other 
Latin American countries in which the presence of this class D carbapenemase 
ranges between 75-100% (144). The similarity of the context of the blaOXA-23-like 
in these isolates with the previously reported Tn2008 in an isolate from another 
city in Bolivia (176) could be due to the mobilization and spread of this 
transposable unit among A. baumannii isolates (177). The gene encoding for 
the aminoglycoside modifying enzyme, aac(3)-IIa was also present in the 
majority of the isolates. The combination of these two antimicrobial resistance 
genes, makes colistin the last resort treatment (113), increasing the risk for 
adverse events (29%) and mortality in these patients (16%). Furthermore, the 
dose of colistin in children is still not accurately established (178, 179).  
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To our knowledge, this is the first report of XDR A. baumannii isolates in 
infants in South America. The high rates of resistance to antimicrobials, 83.3% 
of the isolates were XDR, together with the complicated diagnostics 
(septicaemia and pneumonia the most prevalent) combined with the age of the 
patients (more than the half of them were newborns), increase the 
complications of these infections. XDR A. baumannii infections in infants are 
associated with high morbidity and mortality (28.2%) (180).  We also detected 
that two of the isolates obtained from the hospital environment were XDR and 
MDR, respectively, therefore this environmental presence can lead to a rapid 
spread of the MDR and XDR isolates within the hospital and suggests that 
stricter infection control measures should be introduced. Moreover it was seen 
that the results matched the study of other authors (181) as the hospital 
environmental isolates and those related to medical devices were the ones that 
presented higher rates of biofilm formation, in contrast to what Bardbari et al 
reported (182). Biofilm is a good persistence mechanism that can help these 
strains to survive in the hospital environment for long periods of time and 
contribute to the colonization and spread of these XDR A. baumannii isolates.  
Despite the relatively new creation of the microbiology laboratory service 
in this hospital, an infection control plan has been created because of this work, 
in order to prevent and reduce the number of infections among patients. Further 
studies are needed to track the evolution of the XDR A. baumannii infections. 
The present study demonstrated the predominance and spread of closely 
related XDR A. baumannii isolates in a Children Hospital in Bolivia. The location 
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of the blaOXA-23-like gene in a transposon-like structure could be responsible for 
the dissemination of this carbapenemase-encoding gene among other isolates. 
The high prevalence of XDR A. baumannii clones confers increasing risk to 
children and is of major concern due to the kind of infections and the lack of 
therapeutic alternatives to treat them. 	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2. Acinetobacter baumannii analysis by core genome MLST in 
two hospitals in Bolivia: endemicity of international clone 7 
isolates. 
 
RESULTS 
1. Bacterial isolates 
A total of ninety-five isolates recovered between September 2015 and 
December 2016 in Hospital Materno Infantil and Hospital Viedma, were 
confirmed to be A. baumannii and included in this study.  
 
Figure 17. Location of both hospitals, Hospital Viedma and Hospital Materno-Infantil. 
 
 
Hospital Materno-Infantil 
Hospital Viedma 
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The most common source of the isolates was the respiratory tract, n=34 
(35.8%) followed by wound secretions, n=17 (17.9%); ulcers, n=9 (9.5%) and 
urine culture, n=8 (8.4%). The remaining isolates were recovered from diverse 
sources such as blood culture, catheter, abscesses and exudates. 
 
2. Antimicrobial susceptibility and PCR experiments 
All the isolates were confirmed as A. baumannii by gyrB multiplex PCR 
and the presence of the intrinsic blaOXA-51-like carbapenemase gene.  
MICs were tested by agar dilution. Resistance to ciprofloxacin, 
gentamicin, imipenem, meropenem, and tigecycline was as follows 90.6% 
(n=86); 86.4% (n=82); 53.7% (n=51); 53.7% (n=51) and 61.1% (n=58) 
respectively (Table 9, Figure 18). Colistin MICs were tested by broth 
microdilution (BMD) for all the CRAb isolates which colistin MIC was ≤2 by agar 
dilution. All the isolates but one, were susceptible to colistin. 
By using multiplex PCR, blaOXA-23-like gene was detected in the 51 CRAb 
isolates. No other acquired class D β-lactamases was detected in any of the 
isolates.
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Table 9. Minimum inhibitory concentration of colistin (COL), 
imipenem (IPM), meropenem (MEM), ciprofloxacin (CIP), tigecycline 
(TG) and gentamicin (GEN). Breakpoint interpretations were in 
accordance to EUCAST (116) 
 COL IPM MEM CIP TGC GEN 
MC1 0.5 S* 32 R 64 R >128 R 16 R 32 R 
MC2 1 S 32 R 32 R 32 R 1 S >128 R 
MC3 1 S 32 R 32 R 128 R 4 R >128 R 
MC4 1 S 1 S 1 S 64 R 4 R >128 R 
MC5 1 S 32 R 32 R 128 R 4 R >128 R 
MC6 1 S 32 R 32 R 64 R 1 S >128 R 
MC7 2 S 1 S 2 S 64 R 4 R >128 R 
MC8 1 S 32 R 64 R 32 R 1 S >128 R 
MC9 2 S 1 S 1 S 64 R 4  R >128 R 
MC10 2 S 0.5 S 1 S >128 R 4 R >128 R 
MC12 1 S* 32 R 32 R >128 R 8 R 32 R 
MC14 1 S 32 R 32 R >128 R 8 R >128 R 
MC15 2 S 1 S 1 S >128 R 4 R >128 R 
MC17 1 S* 1 S 2 S >128 R 4 R >128 R 
MC18 0.5 S* 32 R 64 R 128 R 8 R >128 R 
MC19 1 S 32 R 32 R 64 R 1 S >128 R 
MC21 0.5 S* 32 R 32 R 64 R 0,5 S >128 R 
MC22 1 S 32 R 32 R 64 R 1 S 1 S 
MC23 1 S* 1 S 2 S >128 R 4 R >128 R 
MC24 4 R 1 S 2 S >128 R 4R >128 R 
MC25 1 S 0.5 S 1 S >128 R 4 R >128 R 
MC27 1 S 32 R 32 R 32 R 0.5 >128 R 
MC29 0.5 S* 32 R 64 R >128 R 8 R >128 R 
MC30 2 S 2 S 4 S 64 R 1 S >128 R 
MC31 1 S* 32 R 32 R 128 R 8 R >128 R 
MC32 1 S* 32 R 32 R 128 R 8 R >128 R 
MC33 0.5 S* 32 R 32 R 32 R 1 S >128 R 
MC34 0.5 S* 32 R 64 R 128 R 8 R >128 R 
MC35 1 S* 32 R 64 R 32 R 1 S >128 R 
MC38 1 S* 0.5 S 1 S >128 R 2 S >128 R 
MC39 1 S* 32 R 64 R >128 R 8 R 4 S 
MC40 2 S 1 S 2 S >128 R 4 R >128 R 
MC41 2 S 0.5 S 4 S >128 R 2 S >128 R 
MC42 1 S 0.5 S 4 S >128 R 4 R >128 R 
MC43 1 S 0.5 S 4 S >128 R 1 S >128 R 
MC44 0.25 S* 32 R 64 R >128 R 4 R >128 R 
MC45 4 R 0.5 S 2 S >128 R 2 S >128 R 
MC47 1 S* 0.5 S 2 S 128 R 0.5 S >128 R 
MC48 1 S 32 R 64 R 128 R 8 R >128 R 
MC49 2 S 0.5 S 2 S >128 R 4 R >128 R 
MC50 0.25 S* 32 R 64 R 32 R 1 S >128 R 
MC51 0.5 S* 32 R 32 R 128 R 8 R >128 R 
MC52 1 S 2 S 4 S >128 R 4 R >128 R 
MC53 1 S 32 R 32 R 32 R 0.5 S >128 R 
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Table 9. Continued. 
 COL IPM MEM CIP TGC GEN 
MC54 2 S 0.5 S 2 S >128 R 4 R >128 R 
MC55 1 S 0.5 S 2 S 0.5 S 0.25 S 2 S 
MC56 1 S 0.125 S 2 S 1 S 0.25 S 2 S 
MC57 0.5 S* 32 R 32 R 128 R 4 R >128 R 
MC58 1 S 0.5 S 0.5 S 0.5 S 0.25 S 1 S 
MC59 0.25 S* 32 R 32 R 128 R 8 R >128 R 
MC60 1 S 32 R 32 R 64 R 1 S >128 R 
MC61 2 S 1 S 1 S >128 R 4 R >128 R 
MC62 0.25 S* 32 R 32 R 32 R 0.5 S >128 R 
MC63 0.25 S* 32 R 32 R >128 R 8 R >128 R 
MC64 1 S 32 R 32 R 128 R 4 R >128 R 
MC65 2 S 1 S 2 S >128 R 4 R >128 R 
MC66 2 S 0.25 S 0.125 S 0.25 S 0.25 S 2 S 
MC67 1 S 1 S 2 S >128 R 4 R >128 R 
MC68 2 S 0.5 S 2 S >128 R 4 R >128 R 
MC69 1 S 32 R 32 R >128 R 4 R >128 R 
MC70 1 S 1 S 1 S >128 R 4 R >128 R 
MC71 1 S 32 R 64 R 64 R 0,5 >128 R 
MC72 2 S 1 S 1 S >128 R 4 R >128 R 
MC73 2 S 1 S 0.5 S >128 R 4 R >128 R 
MC74 1 S 1 S 2 S >128 R 2 S >128 R 
MC75 1 S* 32 R 64 R 128 R 2 S >128 R 
MC76 2 S 1 S 2 S 128 R 0.5 S 32 R 
MC77 1 S* 32 R 32 R 632 R 0.5 S >128 R 
MC78 1 S 32 R 32 R 128 R 8 R >128 R 
MC79 1 S 0.25 S 2 S 0.5 S 0.25 S 2 S 
MC80 2 S 0.5 S 2 S 128 R 2 S 64 R 
MC81 0.5 0.25 S 1 S 0.5 S 0.5 S 2 S 
MC82 0.5 0.25 S 1 S 0.5 S 0.5 S 2 S 
MC83 1 S 0.5 S 2 S 64 R 0.5 S 16 R 
MC84 0.5 0.5 S 2 S >128 R 4 R >128 R 
MC85 1 S 0.5 S 1 S >128 R 4 R >128 R 
MC86 0.5 S  1 S 1 S >128 R 4 R 64 R 
MC87 1 S* 32 R 64 R 128 R 8 R >128 R 
MC88 1 S 0.25 S 0.25 S 0.125 S 0.5 S 2 S 
MC89 1 S* 32 R 64 R 64 R 8 R >128 R 
MC90 1 S* 32 R 64 R 64 R 4 R >128 R 
MC91 1 S* 32 R 64 R 128 R 8 R >128 R 
MC93 1 S* 32 R 64 R 64 R 8 R >128 R 
MC94 1 S* 32 R 64 R 64 R 8 R >128 R 
MC95 1 S* 32 R 64 R 128 R 8 R >128 R 
MC96 8 R* 32 R 64 R 128 R 8 R >128 R 
MC98 1 S* 32 R 32 R 64 R 8 R >128 R 
MC100 1 S* 32 R 32 R 64 R 8 R >128 R 
MC101 1 S* 32 R 32 R 64 R 8 R >128 R 
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Table 9. Continued. 
 COL IPM MEM CIP TIG GENTA 
MC102 2 S* 32 R 32 R 64 R 8 R >128 R 
MC103 1 S* 32 R 64 R 64 R 8 R >128 R 
MC104 1 S* 32 R 32 R 128 R 4 R >128 R 
MC105 1 S* 32 R 32 R 64 R 1 S >128 R *Colistin MICs for these isolates was tested by BMD. 
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3. DNA extraction for WGS 
The DNA concentration in ng/µL was as follows: MC1, 0.86; MC2, 0.81; 
MC3, 0.67; MC5, 0.97; MC6, 0.89; MC8, 1.09; MC12, 1.12; MC13, 1.74; MC17, 
1.95; MC18, 2.30; MC19, 1.39; MC21, 0.97; MC22, 1.08; MC27, 1.06; MC29, 
1.04; MC31, 2.16; MC32, 1.21; MC33, 1.52; MC34, 1.39; MC35, 0.66; MC37, 
1.12; MC38, 1.95; MC39, 0.84; MC44, 0.69; MC48, 0.99; MC50, 1.22; MC51, 
0.86; MC53, 1.39; MC57, 0.74; MC59, 1.87; MC60, 1.13; MC62, 0.99; MC63, 
1.23; MC64, 1.31; MC69, 0.63; MC71, 0.85; MC75, 2.26; MC77, 2.18; MC78, 
1.55; MC87, 1.59; MC89, 0.90; MC90, 0.89; MC91, 0.96; MC93, 1.06; MC94, 
1.76; MC95, 1.33; MC96, 1.16; MC98, 1.84; MC100, 1.17; MC101, 0.83; 
MC102, 1.97; MC103, 1.09; MC104, 2.04 and MC105, 1.40. 
4. Molecular epidemiology and WGS analysis 
All the CRAb isolates (n=51) and subset of carbapenem susceptible 
isolates recovered along the study period (n=4) were subjected to whole 
genome sequencing in order to investigate their molecular epidemiology as well 
as their antimicrobial resistance mechanisms. A minimum spanning tree 
generated using the cgMLST scheme is shown in Figure 18. Most of the 
isolates, 90.9% (n=50) belonged to ST25 and its SLV ST991 by Pasteur 
scheme (clonal complex 25, CC25) which is associated with IC7, and also had 
blaOXA‐64, the characteristic blaOXA-51 variant from this lineage. Furthermore these 
isolates clustered with IC7 control strains using cgMLST. These three pieces of 
evidence showed that IC7 was predominant among these A. baumannii 
isolates. Following the Oxford scheme these fifty isolates were further 
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delineated into five different groups belonging to CC110 (single locus variant, 
SLV, ST1489, ST1519, ST1529 and ST1518 and double locus variant, DLV, 
ST1528). Furthermore, cgMLST showed that most isolates were not considered 
as transmissions (i.e. the same clone). However, there were five potential 
transmission clusters using a cutoff of 0-10 allelic differences. The other CC25 
isolates differred by up to 110 alleles.  
Five unrelated isolates were also present, differing in ≥ 1950 alleles from 
the IC7 cluster. Three isolates carried the blaOXA-65, were ST79 (IC5) by Pasteur 
scheme and ST233 and DLV ST1520 according to Oxford, and clustered with 
the IC5 control by cgMLST. One isolate clustered with IC4 controls, carried 
blaOXA-51 and was ST15 by Pasteur scheme and ST236 by Oxford. One isolate 
was a singleton, carrying the blaOXA-180 and was ST267/ST942 (Pasteur/Oxford).  
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turbosiesta
Figure 19. Minimum spanning tree generated using Ridom SeqSphere+ for 55 samples ignoring 
missing values. 
• Distance based on columns from A. baumannii cgMLST 2390 targets ACICU. 
• Numbers between the nodes indicate the number of allelic differences. 
· Shaded isolates represent transmission clusters. 
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WGS analysis revealed that in total 51 isolates (88%) carried blaOXA-23 on 
Tn2008. Other genes conferring resistance to antibiotics such as 
aminoglycosides (strA, n=49; strB, n=49; aac(3’)-IIa, n=49; aac(3’)-VIa, n=5; 
aadA1, n=3; aadB, n=3); β-lactams (blaADC-25, n=55; blaTEM-1A, n=4; blaTEM-1B, 
n=2); sulphonamides (sul2, n=52); tetracyclines (tet(B), n=48); trimethoprim 
(dfrA, n=3) and phenicols (floR, n=3) were also present.  The gene aac(3’)-VIa  
was located on a transposon, TnaphA6,  in five of the isolates. Results on the 
detected resistance genes of the isolates are summarised in Table 10.  
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5. Location of resistance genes  
S1-nuclease pulsed field gel electrophoresis (S1-PFGE) and Southern 
blot hybridization were perfomed to determine the plasmid size and the 
plasmid/chromosomal location of blaOXA-23 and strA in a selection of isolates 
representing all the present ICs and unique Oxford STs (n=10) (Figure 19).	  
Southern blot revealed that blaOXA-23 was located on the chromosome in all 
tested isolates (n=8). However, the strA gene was encoded on a 184 Kb 
plasmid in all the IC7 isolates as well as in the singleton; the IC4 isolate carried 
the strA gene on a ∼150 Kb plasmid. strA was always linked to strB, sul2, 
aac(3)-IIa and tet(B) in the IC7 isolates, as identified by contig overlap and 
confirmed using PCR-based  gap closure. No tet(B) gene was detected in the 
IC4 isolate. In contrast, Southern blot revealed that strA was located on the 
chromosome in the IC5 isolates and was associated with strB, sul2 and floR.  
Additionally, the IC5 isolates harbored aadA1 and aadB on a 6.2 Kb plasmid 
(Table 10, Table 11). 
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DISCUSSION 
Formerly IC7 isolates have been described in some Latin American 
countries such as Paraguay or Argentina, but normally they were sporadic and 
not associated with outbreaks (142). However, IC7 was the most prevalent 
group in studies performed in Bolivia or Uruguay (141), which is in concordance 
with our findings. We found only one carbapenem-resistant IC4 isolate and 
three carbapenem-susceptible IC5 isolates, although, IC5 is the prevalent 
lineage in Latin America, the so called Pan-American clone, followed by IC4 
(141, 144, 174, 183). The prevalence of IC7 isolates suggests a change in the 
epidemiology of carbapenem-resistant A. baumannii isolates in Bolivia and in 
particular the city of Cochabamba, when comparing these results to previous 
studies (183). 
According to the Pan American Health Organization (PAHO) annual 
study, in Bolivia in 2010 19% of Acinetobacter spp. were resistant to imipenem 
and 7% to meropenem; in 2014, 51% of A. baumannii isolates were resistant to 
imipenem and 57% to meropenem (184, 185). In our study, similar results to 
those obtained by the PAHO in 2014 were found, and the resistance rates were 
similar to the ones in Colombia, where the presence of ST229 (Oxford) isolates 
(with blaOXA-64), that belong to IC7, have also been reported (186, 187). High 
rates of carbapenem resistance in Hospital Materno Infantil have been already 
described in a previous study (149). In addition, the CRAb isolates present 
higher resistance rates to other antimicrobials such as ciprofloxacin and 
gentamicin, in comparison to the non-CRAb isolates, thus complicating 
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antimicrobial treatment options.	   When analyzing the population within both 
hospitals, it can be seen that different clusters are associated with each of 
them; almost all the isolates from Hospital Materno Infantil were ST991Pas 
while ST25Pas isolates were mainly found in Hospital Viedma, just two ST25Pas 
isolates belonged to Hospital Materno Infantil. Some ST991Pas isolates were 
also isolated in Hospital Viedma (n=8), which can suggest that there is cross-
transmission from Hospital Materno Infantil to Hospital Viedma. 
Diverse blaOXA-51 variants such as blaOXA-65, blaOXA-64, blaOXA-51 or blaOXA-66 
have been reported in Latin America but until now no blaOXA-180 carbapenemase 
had been found (144). Moreover, Sennati et al described the presence of 
Tn2008 in a ST25 (Pasteur) A. baumannii isolate from Bolivia that also carried 
blaOXA-64 (176). In this transposon, ISAba1 is not only serving as a promoter for 
the carbapenemase encoding gene, but is also involved in the mobilization of 
the gene (177). This carbapenemase-encoding vehicle has spread worldwide 
(177), and similar to what Sennati et al found, in our isolates from the current 
study Tn2008 is present in all the isolates belonging to ST25 (IC7) as well as in 
the ST15 isolate (IC4). Thus the mobilization of Tn2008 has led to its 
prevalence among diverse ICs, increasing the resistance rates to carbapenems 
(177). Furthermore, our group of isolates carried resistance genes encoded on 
different structures such as transposons or plasmids that can also spread and 
confer antimicrobial resistance to other groups of drugs such as 
aminoglycosides, which in combination with carbapenem resistance, drastically 
reduces the therapeutic options (114).  
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In conclusion, IC7 was endemic in these two Bolivian hospitals, 
clustering together 50 isolates with different resistomes. In the present study we 
report the dissemination of several clones of CC25 (IC7) carrying the 
carbapenem-resistance determinant Tn2008. Although some studies are being 
carried out in South America, the situation in Bolivia is not very well known 
although epidemiological information is essential to implement infection control 
strategies in the hospital settings. To the best of our knowledge, this is the first 
study carried in Bolivia in which the molecular epidemiology of all the CRAb 
isolates has been analysed and the obtained data will be useful in order to know 
the A. baumannii population dynamics within these two hospitals.  
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3. Plasmid content in three Bolivian Acinetobacter baumanni 
isolates belonging to different International Clones. 
RESULTS AND DISCUSSION 
Three isolates representing all ICs from the previous study were selected 
in order to deeper study their plasmid content; MC1, an IC7 carbapenem-
resistant isolate, isolated from Hospital Materno-Infantil; and two isolates from 
Hospital Viedma; MC23, a carbapenem susceptible isolate belonging to IC5, 
and MC75, a carbapenem-resistant IC4 isolate (Figure 20, Table 12). MC1 was 
isolated from a catheter in a patient with a bloodstream infection; MC23 from an 
urine sample and MC75 from a ulcer.  
Table 12. Plasmid content according to S1-PFGE 
Isolate Plasmids* 
MC1 ~180 Kb ~8 Kb  
MC23 ~60 Kb ~8 Kb ~6 Kb 
MC75 ~150 Kb ~14 Kb  
    
*Size determined by PFGE. 
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Primers were designed for confirming the plasmid structure in MC1 and 
MC23 isolates. PCR mapping confirmed the contigs’ overlaps (Table 13). 
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Figure 21. S1-PFGE and Southern blot with DIG-
labelled strA probe. Left hand side shows S1-PFGE of 
isolates MC1, MC23 and MC75. All the plasmids but 
the 6 Kb can be seen. Right hand side correspond to 
the Southern blot-hybidization of the same isolates 
with strA, which is located on the chromosome in 
MC23 and in plasmids in MC1 and MC75.. 
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For the ~8 Kb plasmid in MC1 two primers were designed L64 and L65. 
The plasmid structure was confirmed by PCR. The same results were obtained 
for MC23, showing that both isolates carried the same plasmid.  
Another two pairs of primers were designed to confirm plasmid 
assemblies in MC23. M5-M6 primers to confirm the ~6 Kb plasmid and M17-
M18 to confirm the ~60 Kb plasmid. The structure of each plasmid was 
confirmed by PCR products confirmed these two plasmids as well.  
Long-read sequencing allowed us to confirm the plasmids’ scaffolds and 
assemblies using hybridSpades, that uses both short and long reads, confirmed 
both the scaffold and the genes sequences (Table 14). 
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Annotation of pMC1.1 (39% GC content) revealed many different IS such 
as	   IS1006, IS1007, IS1008, ISAcsp1 (from Acinetobacter spp.), IS91 family, 
ISAha2 (from Acinetobacter haemolyticus), ISAba11, ISAba12 and IS17. This 
plasmid carried a mercuric resistance operon, similar to an already described 
mercuric transposon in an IC1 A. baumannii 200 Kb plasmid (pA297-3, this 
isolate A297/RUH875 was recovered in The Netherlands in 1984) but lacking 
the merP open reading frame (128), that encodes for a protein that specifically 
binds to a mercuric ion in the periplasm and passes it to merA, a cytoplasmic 
reductase, via the transport protein merT (188). Different antimicrobial 
resistance determinants such as strA, strB, aac(3)-IIa and aac(6’)-Ian, 
conferring resistance to aminoglycosides, sul2 conferring resistance to 
sulphonamides and tet(B) conferring resistance to tetracycline were also 
present in two regions. The region of the plasmid carrying strAB and sul2 
shared a great homology (99%) with Tn6172, located in pA297-3 as well. 
However, arsR, tetR and tet(B) genes were also located within the transposon 
together with an ISCR2 transposable element (IS91 family). The ISCR2 element 
has been described related to different antimicrobial resistance genes, 
especially to sul2, contributing to their mobilization thanks to a rolling circle 
transposition mechanism (189). This structure was similar to formerly described 
ones such as those in Argentinan A. baumannnii isolates and another one in an 
ST25 A. baumannii isolate from Australia (131), however the location of tetR-
tetB genes was different; they were located between glmM and arsR suggesting 
a possible later insertion of these two genes in different positions in the 
transposon (190). In addition, the same inverted repeats (IR) generated by the 
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insertion of the transposon were also found in the pMC1.1 plasmid, and with the 
similar backbone to pA297-3 suggest a common origin of these two plasmids. 
The genes aac(3)-IIa and aac(6’)-Ian were associated with two IS6 family 
insertion sequences and bracketed by two ISCR1 in an inverted orientation The 
ISCR1  belong also to the IS91 family and have been described along with 
class 1 integrons and antimicrobial resistance genes (189), however to the best 
of our knowledge, these IS have never been described with aac(3)-IIa or 
aac(6’)-Ian. Different conjugative protein encoding genes were also found in this 
plasmid, traW, traY, traJ,  traI, trbN as well as genes involved in plasmid 
partition and replication parB/repB and xerC, that are related to segregational 
stability of plasmids. This plasmid encoded also for a system called BREX type 
1 (bacteriophage exclusion) which has been described to be involved in phage 
resistance (191). 	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Figure 22. Map of plasmid pMC1.1. 
	  
The 8,7 Kb plasmids found in MC1 and MC23 (pMC1.2 and pMC23.2) 
were found to be identical, with a GC content of 34.3%. Annotation of this 
plasmid revealed ORFs encoding for a RepB replicon, a toxin-antitoxin system 
(BrnT-BrnA), that is involved in vertical stability; TonB-dependent receptor, 
related to the transmission of signals from the outside of the cell leading to 
transcriptional activation of target genes; septicolysin encoding gene, that is a 
cytolytic enzyme toward eukaryotc cells and is involved in pathogenesis, as well 
as sel1 gene, that encodes for a protein that has been described in diverse 
prokaryotic genera and it has an important role in virulence. Some other 
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hypothetical proteins were also present. This small plasmid has been often 
found in IC1 A. baumannii isolates (128). 
	  
Figure 23. Map of plasmids pMC1.2/pMC23.2.. 
	  
The biggest plasmid present in MC23 was pMC23.1, it belonged to GR6 
according to its replicase, repAci6. Its GC content was 33.7% and almost all of 
its putative protein encoding genes were related to conjugative plasmid transfer 
in a tra locus, traI (rlx), that is a relaxase; the genes traL (virB3), traE (virB5), 
traK (virB9), traB (virB10), traV (virB7), traC (virB4), trhF (Pep), traW (tivF8), 
traU (tivF7), trbC (tivF9), traN (tivF6), traF (tivF2), traH (tivF4), traG (tivF3) and 
traD; that are part of type 4 (T4SS) secretion system. This T4SS is able to 
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secrete or take up both proteins and DNA, i.e. leading to natural competence 
(192). Two toxin encoding genes were present in the plasmid, relE and zeta 
toxin, but no antitoxins were found as in a very similar plasmid (pAC30c) in an 
A. baumannii isolate belonging to ST195 (IC2) (129); the stability genes 
parA/parB  were also present.  
The backbone of pMC23.1 and pAC30c was very similar, only a few 
differences were discovered. pMC23.1 lacked some hypothetical proteins 
present in pAC30c and the region encoding for tellurite resistance (telA gene 
and IS66) while traD, a cupin-like protein, (that is a superfamily of enzymes 
including dioxygenases, decarboxylases, hydrolases or isomerases); HlyD 
protein, that exports proteins from the cytosol to the outside of the cell, and an 
ABC transporter were not present in pAC30.  
	  
Figure 24. Map of plasmid pMC23.1. 
	  
	   RESULTS AND DISCUSSION 	  
	   	   	  134	  
Another small plasmid was present in the isolate MC23, pMC23.3 (39.2% 
GC content), and was found to have 100% similarity with an already described 
plasmid, pRAY, encoding resistance to gentamicin, kanamycin and tobramycin 
(aadB gene) together with mobA and mobC genes, which are thought to encode 
mobilization proteins (132). Many similar plasmids have been found in diverse 
A. baumannii ICs from different locations, suggesting a similar origin of all of 
them, and a subsequent diversification in their evolution. In accordance with 
other studies, no rep gene was found in the sequence, supporting the idea of 
the presence of a mechanism of replication relying on the host RNA polymerase 
(132). 
	   	  
Figure 25. Map of plasmid pMC23.3. 
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Analysis of pMC75.1 revealed that it was 92% equal to pMC1.1, it also 
carried a Tn6172, in which antimicrobial resistance genes such as sul2, strB 
and strA were encoded but lacking tet(B) and arsR that were present in 
pMC1.1. The GC content of this plasmid was 37.49%. The mer operon was also 
found in this plasmid, merR, merT, merP, merC, merA and merD and many 
genes encoding conjugative transfer proteins, traY, traW, traI, traJ, trbA and 
trbN. Some genes of the BREX type 1 system were also present, which encode 
proteins involved in bacteriophage exclusión, brxC, pglX, pglZ and brxL. A stbA 
gene was found, the protein encoded by this gene has a role in plasmid stability 
as well as parA/parB. Several IS were also present, ISAba1, ISAba125, 
ISAba14, ISAba42, IS1007 and ISAha2. However, this plasmid lacked the 
transposon carrying aac(3)-IIa and aac(6’)-Ian 
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Figure 26. Map of plasmid pMC75.1. 
 
The 13.9 Kb plasmid, pMC75.2 with a GC content of 40.3%, carried the 
extended-spectrum β-lactamase blaTEM-1B and the aminoglycoside resistance 
gene aac(3)-IIa flanked by two IS15DIV; a toxin-antitoxin system, brnT/brnA; a 
TonB-dependant receptor, a septicolysin gene and mobA/mobS, which are 
involved in plasmid mobility. The replicon of this plasmid belonged to the RepB 
(Rep-3 superfamily) with 100% homology. 
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Figure 27. Map of plasmid pMC75.2. 
 
1.1. Resistance islands 
In contrast to what was found  in MC1, strA was located in a resistance 
island in the chromosome in isolate MC23 (RI1.MC23), in addition, another 
resistance island was also found in this isolate (RI2.MC23). 
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The resistance island in which strA gene was found, carried other 
antimicrobial resistance genes such as sul2, floR and strB. Diverse IS were 
found as well, the resistance island was bracketed by two copies of a 
transposase of IS4 family in reverse orientation. Two genes involved in 
conjugation were also present in this structure, this finding suggests the 
possible insertion of this structure from a plasmid. 
	  
Figure 28. Map of resistance island RI1.MC23. 	  
The second resistance island found in this isolate was RI2.MC23, that 
carried a typical structure from class 2 integrons, dfrA-sat2-aadA1-ybeA-ybfA-
ybfB-ybgA, located between the Tn7 transposition module tnsABCDE and a 
non-functional Intl2 integrase. Additionally, a Tn3 transposon was found 
inserted in the Tn7 transposon, carrying three genes, tnpA, encoding for a Tn3 
transposase; tnpR encoding a Tn3 resolvase and the antimicrobial resistance 
gene blaTEM-1A.  
 
Figure 29. Map of resistance island RI2.MC23. 
RI1.MC23 
17,184 bp 
RI2.MC23 
19,020 bp 
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4. Identification of Acinetobacter seifertii isolated from Bolivian 
hospitals. 
RESULTS 
In three patients admitted to two different hospitals in Cochabamba, three 
isolates were recovered and identified as Acinetobacter sp. using phenotypical 
methods by the hospital laboratories according to the following criteria: Gram-
negative by Gram stain; non-fermenter (K/K) by triple sugar iron agar; negative 
motility in brain heart infusion broth; negative oxidase; negative gelatin 
liquefaction; negative haemolysis. These data let to the assumption that the 
isolates were A. baumannii, and  the patients were managed accordingly. The 
first isolate was recovered from a pressure ulcer (isolate MC37) in a 33 year-old 
man from Hospital Viedma in February 2016. The other two isolates were 
obtained from Hospital Materno-Infantil in March and April 2016, respectively. 
The first patient was a 59 year-old woman with an intraabdominal abscess from 
which the sample was taken (isolate MC13), the other isolate was recovered 
from a catheter in a 2 year-old child diagnosed with sepsis (isolate MC16).  
All three isolates were susceptible to ciprofloxacin (MICs: 0.5-1 µg/mL), 
gentamicin (MICs: 0.5-1 µg/mL), imipenem (MIC: 0.125 µg/mL), meropenem 
(MIC: 0.25 µg/mL) and tigecycline (MIC: 0.5 µg/mL) as determined by agar 
dilution and they were also susceptible to colistin (MIC: 2 µg/mL) according to 
broth microdilution. 
Semi-automated identification using the VITEK®2 GN ID card was only 
able to assign the isolates to the A. baumannii complex (containing also 
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Acinetobacter pittii, Acinetobacter calcoaceticus and Acinetobacter 
nosocomialis) while MALDI-TOF MS  results showed a mixed pattern of A. 
baumannii (scores ranging from 2.02-2.34) and A. pittii (scores ranging from 
1.89-2.08) (Table 15). 
The band patterns obtained by gyrB multiplex PCR were inconclusive as 
well; they included bands specific for both A. pittii and A. baumannii. No blaOXA 
genes were detected including the blaOXA-51-like, which is intrinsic to A. baumannii 
(Table 15). 
Because no conclusive results were obtained by these methods, whole 
genome sequencing was performed for the identification at the species level. 
SpeciesFinder failed to resolve the species identification and A. 
baumannii was the first hit using KmerFinder, which we considered as a non-
valid result because no blaOXA-51-like gene was found in any of the three isolates 
(Table 15). Partial rpoB analysis clustered the isolates with A. seifertii, therefore 
further analysis of the three isolates was carried out. 
MLSA revealed that the percentage of similarity within species was 
above 97.8% while interspecies similarity was below 97.0%. The highest 
similarity values obtained positioned the three isolates together with A. seifertii. 
Furthermore, a neighbour-joining tree was constructed based on the seven 
concatenated housekeeping genes of the Pasteur scheme (MC13, ST994; 
MC16, ST994 and MC37, ST1064) and the three isolates fell within the cluster 
of A. seifertii strains (Figure 21). 
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Figure 30. MLSA tree based on the seven concatenated housekeeping genes. 
Additionally, dDDH results were congruent with MLSA, showing values 
above 70% between the three studied isolates and A. seifertii NIPH 973T (Table 
16). 
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In addition, ANIb also supported these results as all three isolates had 
values well above the 95% for A. seifertii (Table 17). Isolates MC13 and MC16 
presented highly similar genomes as determined by ANIb and dDDH values, 
99.9% and 100% respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17. ANIb results. 
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DISCUSSION 
While A. baumannii remains the most frequently recovered species of the 
genus Acinetobacter from clinical samples, there are increasing reports of other 
Acinetobacter species being involved in human infections (4, 103). To the best 
of our knowledge, this is the first report of A. seifertii in Bolivia causing different 
infections and the second report from South America (4). 
A. seifertii infections and their outcomes are not well characterized, 
nonetheless in-vitro virulence-associated phenotypes such as increased biofilm 
formation, cell adherence and resistance to human serum were found in Korean 
isolates (193). Both cell adherence and biofilm formation could have contributed 
to the catheter-related infection, ulcer infection and abscess formation.  
Although A. seifertii has now been reported to cause serious infections, it 
is in general susceptible to antimicrobials (103), but in some cases plasmids 
carrying antimicrobial resistance genes have been described within this species 
(4, 79). The acquisition of different antimicrobial resistance determinants is 
worrying because it narrows the therapeutic options. Furthermore, having the 
correct Acinetobacter species identification is important to understand the 
epidemiology and the clinical impact of the various Acinetobacter species. In 
our case, the standard tests used for species identification in the diagnostic 
laboratories were not adequate, reflecting that newer species such as A. seifertii 
are not yet included in the databases of these semi-automated identification 
methods. Although rpoB sequence analysis identified the isolates as A. seifertii, 
further analysis was necessary to confirm the result. In fact, as already stated 
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by Khosravi et al, identification based on a single gene sequence may not 
always be fully reliable (194), and underreporting of A. seifertii and other 
Acinetobacter species may be occurring due to the difficulties to identify them. 
Moreover, the limitations of using VITEK®2 and also rpoB sequences for 
identification of Acinetobacter spp. have already been described (83, 194). In 
addition, the necessity to include this species in the Bruker taxonomy database 
has been already discussed (82).  
Nowadays, the most reliable methods for bacterial identification are 
based on the whole genome sequence [1,19,20], and our results based on 
these methods were congruent and allowed us to identify the species of the 
three isolates. It is important to be able to differentiate Acinetobacter species 
since the antibiotic susceptibilities and clinical outcomes can be very diverse 
among the different Acinetobacter species (82, 96). 
In conclusion, the phenotypic and semi-automated identification methods 
are unreliable for identification of A. seifertii. In this study, identification of the 
three isolates to the species level was not possible until high-resolution 
molecular methods were used. A. seifertii appears to be a challenge as various 
studies have described misidentification of this species. Even if its prevalence, 
epidemiology, or virulence are not yet well known, an improvement in diagnostic 
laboratories should be made in order to include this organism of growing 
importance. Further studies should be carried forward in order to better 
characterize this species and analyse its incidence and clinical impact. 
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GENERAL DISCUSSION 
Infections caused by MDR A. baumannii have been increasingly reported 
worldwide together with the presence of carbapenem resistance. Carbapenems 
are the antimicrobials of choice to treat infections caused by MDR Gram-
negative bacteria, but with the increase in carbapenem-resistance among A. 
baumannii isolates, the antibiotic therapy can be compromised. These 
carbapenem-resistance mechanisms can be found in very diverse structures 
such as an IS overexpressing the intrinsic blaOXA-51-like in A. baumannii; 
transposons carrying antimicrobial resistance genes located in both the 
chromosome or plasmids, or plasmids themselves carrying a wide variety of 
genes encoding antimicrobial resistance as well as virulence and other features; 
independently of the IC.  
It is important to study the dynamics and resistomes of the bacterial 
populations in order to understand the situation in each hospital or unit, and be 
able to handle the infection control plan appropriately. 
In this study the molecular epidemiology of a total of 87 A. baumannii 
isolates recovered from Bolivian hospitals was analyzed. The majority of these 
isolates belonged to different clones of IC7 (n=76), but there was also presence 
of IC4 and IC5 as sporadic cases. The epidemiological situation in these 
Bolivian hospitals differs from that in other Latin American studies. For example, 
IC4 (CC15P) has been described in a study comprising 69.4% of the isolates 
between 2009-2011 in a Brazilian hospital, all these isolates carried the 
carbapenem-resistance gene blaOXA-23 (142). This IC has been also found in 
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other Latin American countries such as Argentina and Chile, normally 
representing unrelated or sporadic cases (3). In the previously mentioned study, 
IC5 (CC79P) comprised just 10% of the isolates, it appears to be the most 
prevalent among other studies carried in Latin American countries as well (147, 
148). IC5 has been mainly isolated in North, Central and South America and it 
received the name Pan-American clone because of this (3). On the other hand, 
IC7 (CC25P) has been reported worldwide and associated with diverse 
antimicrobial resistance determinants such as blaNDM-2, blaOXA-72, blaOXA-58 and 
blaOXA-23 (3, 139, 149). In Latin America, this clone has been reported in 
hospitals in Brazil, Paraguay, Bolivia, Argentina, Colombia, Mexico and 
Venezuela (3, 141, 142). Two sporadic A. baumannii isolates belonging to IC5 
and IC7, respectively, have recently been isolated from neonates in a hospital in 
Brazil (150), while in Colombia most of the isolates recovered in a 2017 study 
belonged to CC636Ox (IC5) followed by CC110Ox (IC7) (151).  
The prevalence of endemic IC7 A. baumannii isolates in these two 
hospitals suggests a change in their situation when compared to previous 
studies as well as a difference with other neighbouring countries (183). 
All the carbapenem resistant isolates carried the blaOXA-23 gene in a 
Tn2008, which has been previously described in diverse ICs (177, 195) 
including IC7 isolates recovered from a Hospital in the same city (176). This 
Tn2008 contributes to the overexpression of the carbapenemase gene and to 
its mobilization.  
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There was a high prevalence of genes conferring aminoglycoside 
resistance such as aac(3)-IIa, strA and strB; tetB conferring resistance to 
tetracycline or sul2 conferring resistance to sulphonamide. These genes were 
found both in the chromosome and plasmids, demonstrating the plasticity of the 
A. baumannii genome and the mobility of these genes within mobile genetic 
elements such as transposons or plasmids.  
The endemicity of IC7 isolates encoding the blaOXA-23 carbapenemase 
gene mirrors the importance of the epidemiological analysis and the 
establishment of adequate infection control measures to avoid the spread of the 
clones within the hospital and the possible mobilization of antimicrobial 
resistance mechanisms within A. baumannii or even to other species or genus. 
In addition to the importance of studying the epidemiology and 
antimicrobial resistance mechanisms of A. baumannii in every hospital or ward, 
the relevance of correctly identifying the species within the genus and difficulties 
in this process have been also discussed. 
As infections caused by A. baumannii have been increasingly reported in 
the last decades together with its resistance to antibiotics, specially 
carbapenems, special control measures are needed in order to prevent its 
spread causing outbreaks. Other species of the genus are being reported lately, 
and as well as in the case of A. baumannii, several carbapenem resistance 
mechanisms have been described related to these other species. It seems that 
the Acinetobacter genus has a great ability to acquire antimicrobial resistance 
determinants and become a threat in hospitals. 
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1. XDR A. baumannii isolates were prevalent in a Children Hospital causing 
diverse types of infections. 
2. Tn2008 was shown to be the main vehicle of blaOXA-23 in different ICs, 
contributing to its overexpression and mobilization. 
3. IC7 A. baumannii is endemic in the two studied hospitals, this situation 
differs from that in other neighbouring countries. Sporadic cases of IC4 
and IC5 were also present. 
4. Antimicrobial resistance genes are encoded in mobile genetic elements 
contributing to their overexpression and spread. There was a high 
prevalence of aminoglycoside resistance genes found both in the 
chromosome and plasmids. 
5. Endemicity of IC7 A. baumannii isolates and the genome plasticity of 
Acinetobacter spp. mirrors the importance of correctly establish infection 
control measures. 
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ABBREVIATIONS	  
°C Celsius degrees 
µg Microgram 
µL Microlitre 
AAC Acetyltransferase 
Ab group Acinetobacter baumannii group 
ABC ATP-Binding Cassette transporters 
AFLP Amplified Fragment Length Polymorphism 
AMEs Aminoglycoside modifying enzymes 
ANI Average Nucleotide Identity 
ANT Adenyltransferase 
APH Phosphotransferase 
ARDRA Amplified Ribosomal DNA Restriction Analysis  
ATCC American Type Culture Collection 
bla β-lactamase gene 
blaGES Guiana extended-spectrum β-lactamase 
blaGIM German imipenemase 
blaIMP Imipenemase metallo-β-lactamase 
blaKPC Klebsiella pneumoniae carbapenemases  
blaNDM New Delhi metallo- β-lactamases 
blaSPM Sao Paulo metallo- β-lactamase 
blaVIM Verone integron-encoded metallo- β-lactamase 
BLAST Basic Local Alignment Search Tool 
BMD Broth microdilution 
bp Base pair 
CC Clonal Complex 
CDC Centers for Disease Control and Prevention 
CFU Colony formation units 
cgMLST Core genome multi locus sequence typing 
CIP Ciprofloxacin 
CLSI Clinical and Laboratory Standards Institute 
cm Centimeter 
COL Colistin 
cpn60 60-kDa chaperonin 
CRAb Carbapenem-Resistant Acinetobacter baumannii 
CSB Cell suspension buffer 
dDDH digital DNA-DNA hybridization 
DDH DNA-DNA hybridization 
DLV Double Locus Variant 
DNA Deoxyribonucleic acid 
DR Direct repeat 
dsDNA Double stranded DNA 
ECDC European Centre for Disease Prevention and Control 
EDTA Ethylenediaminetetraacetic acid 
ES EDTA 0.5 M pH 9.0 + N-Lauroylsarcosine sodium salt 1% 
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ESBL Extended spectrum β-lactamases 
EUCAST European Committee on Antimicrobial Susceptibility Testing  
FDA Food and Drug Administration 
fusA Elongation factor EF-G 
GC Guanine-Cytosine 
gdhB Glucose dehydrogenase B 
GENTA Gentamicin 
gltA Citrate synthase 
gpi Glucose-6-phosphate isomerase 
g Gram 
gyrB DNA gyrase subunit B  
h Hours 
HCCA α-Cyano-4-hydroxycinnamic acid 
HGT Horizontal Gene Transfer 
IC International Clone 
ICU Intensive Care Unit 
IPM Imipenem 
IR Inverted repeat 
IS Insertion sequence 
Kb Kilobase 
KDa Kilo Dalton 
L Litre 
LB Luria-Bertani 
LPS Lipopolysaccharide 
MALDI-TOF MS Matrix-Assisted Laser Desorption-Time Of Flight Mass Spectrometry 
MATE Multi-drug and toxic compound extrusion 
MBL Metallo-β-lactamase 
MDR Multidrug-resistant 
MEM Meropenem 
MFS Major facilitator superfamily 
mg Milligram 
MIC Minimum inhibitory concentration 
min Minute 
MLSA Multi locus sequence analysis 
MLST Multi Locus Sequence Typing 
NaCl Sodium chloride 
NCTC National Collection of Type Cultures 
ng Nanogram 
nt Nucleotide 
O/N Over-night 
OMP Outer membrane protein 
OMV Outer membrane vesicle 
ORF Open reading frame 
OXA Oxacillinase 
PAHO Pan American Health Organization 
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PBP Penicillin-binding protein 
PCR Polymerase-chain reaction 
PDR Pandrug-Resistant 
PFGE Pulsed Field Gel Electrophoresis 
pyrG CTP synthase 
RAST Rapid Annotation Subsystem Technology  
rDNA Ribosomal DNA 
recA Homologous recombination factor 
RI Resistance island 
RNA Ribonucleic Acid 
RND Resistance-nodulation-cell division 
rplB 50S ribosomal protein L2 
rpoB RNA polymerase subunit B 
rpoD RNA polymerase sigma factor 
rRNA Ribosomal RNA 
RT Room Temperature 
s Second 
SLV Single Locus Variant 
SMR Small multi-drug resistance families 
SSC Saline-sodium citrate buffer 
ST Sequence Type 
T4SS Type 4 Secretion System 
TBE Tris-borate-EDTA Buffer 
TE Tris-EDTA buffer 
TIG Tigecycline 
tRNA Transfer RNA 
UV Ultraviolet 
V Volts 
vol Volume 
WGS Whole Genome Sequencing 
wt Weight 
XDR Extensively drug-resistant 
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Apendix 2. Buffers  	  
Buffers for ApaI-PFGE 
TE, Tris-EDTA pH 8.0 
10 mM TrisHCl 
1 mM EDTA 
PLUG LYSIS  
(1 mL/sample) 
6mM Tris-HCl  pH8  
1M NaCl 
0.1 M EDTA 0.5M pH8 
0.2% Sodium deoxycholate 
0.5 % N-Lauroylsarcosine sodium salt 
0.5 % Brij®58 
0.5 mg Lisozyme (50 mg/mL) 
PROTEINASE K DIGESTION  
(1 mL/sample) 
0.12 mg Proteinase K  
20% ES (EDTA 0.5 M pH 9.0 + 
N-Lauroylsarcosine sodium salt 1%) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Buffers for S1 and I-CeuI PFGE 
CSB, Cell suspension buffer pH 8.0 
100 mM Tris-HCl 
100 mM EDTA 
TE buffer pH 8.0 
10 mM Tris-HCl 
1 mM EDTA 
Cell lysis buffer, CLB pH 8.0 
50 mM Tris-HCl  
50 mM EDTA 
1 % N-Lauroylsarcosine sodium salt  
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Buffers for Southern blot 
Denaturation solution 
0.5 M NaOH 
1.5 M NaCl 
Neutralization solution 
0.5 M NaOH 
1.5 M NaCl 
Hybridization buffer 
50% formamide 
5x SSC 
2.5% blocking reagent 
0.1% N-Lauroylsarcosine sodium salt 
0.02% SDS 
Low Stringency buffer 
2x SSC 
0.1% SDS 
High Stringency buffer 
0.1x SSC 
0.1% SDS 
	  
 
